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Abstract 
With the increase in recent years in the prevalence of malaria, and in drug 
resistance of Plasmodium falciparum, there has been much interest in natural 
plant products for new antimalarials with novel modes of action against 
Plasmodium. Artemisinin or Qinghaosu is one such antimalarial isolated from a 
Chinese herb, Anemisia annua (Asteraceae) and it is currently undergoing phase I 
and II clinical trials. The Southern African species, Artemisia afra (African 
wormwood, wildeals, lengana) is commonly used by local traditional healers for 
symptoms of malaria, in particular fever. Thus it seemed appropriate to 
investigate this species for antimalarial activity. 
Crude petroleum ether soxhlet extracts of Anemisia afra had demonstrated 
antimalarial activity against Plasmodium falciparum, FCR-3, cultured in vitro. 
The IC50 values ranged from 5-I3µg/ml. The extract from leaves and flowers was 
then screened against D10 (chloroquine-sensitive) and FAC8 (chloroquine-
resistant) P. falciparum, in vitro, with IC50 values of 1.03µg/ml and l.5µg/ml 
respectively. This extract was fractionated by column chromatography using silica 
gel-60 and the fractions obtained were screened for antimalarial activity. The 
most active fraction had an IC50 of 0.5µg/ml against D10 and FAC8. Using TLC 
and HPLC-UV analysis with pure artemisinin as a standard, no artemisinin could 
be detected in this fraction. This result was confirmed by thermospray LC-MS 
analyses. Purification of this fraction yielded ultimately a single pure compound; 
a clear colourless oil identified by MS and NMR analyses as hydroxydavanone. 
The compound was screened against a variety of P. falciparum strains with 
varying degrees of sensitivity and resistance to both chloroquine and mefloquine. 
Their sensitivity against artemisinin was also established. IC50 values obtained for 
the isolated pure compound against P. falciparum ranged from 0.87 to 
2.54µg/ml. The IC50 values obtained for general cytotoxicity of the crude extract 
Vl 
and isolated pure compound against RAT-I fibroblast cells were 34.78 ± 8.23 and 
6.29 ± 0.95 µg/ml (n=4) respectively. Thus the crude extract and isolated pure 
compound exhibited a greater antimalarial than cytotoxic effect. Hence, there are 
implications for A. afra to be used as a phytomedicine for the treatment of 
malaria. In vivo studies are recommended for hydroxydavanone in order to fully 
assess its potential for clinical use. 
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Drug resistance is a major obstacle to the successful treatment and control of 
malaria. Chloroquine resistance, in particular, has become widespread in many 
parts of the world where Plasmodium falciparum is endemic. Resistance to other 
drugs such as amodiaquine, sulfadoxine-pyrimethamine, quinine, and 
mefloquine, exists to varying degrees in certain endemic regions (1,2). The 
limited therapeutic options for drug-resistant P. falciparum, and the 
development of resistance to drugs other than chloroquine, has led to the urgent 
need to search for new antimalarials. As a result, there has been renewed 
interest in plants either as a source of new antimalarials or in providing template 
molecules for novel structures with novel modes of action. 
The recent chemical, biochemical and clinical studies of the Chinese 
antimalarial, artemisinin, has given considerable impetus to the search for new 
antimalarials from plants. Artemisinin was isolated in 1971 as the active 
principle from the Chinese herb Artemisia annua Linn. (Asteraceae) which had 
been used for more than 2 000 years to treat febrile illnesses (3). Artemisinin 
however, is poorly soluble in water or oil and hence a number of water-soluble 
derivatives (artesunate and artelinate) and oil-soluble derivatives (artemether and 
arteether) were synthesized. These drugs are currently undergoing clinical trials 
(1,4). 
The Southern African variety of Artemisia, Artemisia afra Jacq. (Asteraceae) 
had been identified as a common plant used by local traditional healers for the 
treatment of fever and symptoms of malaria (5). This led to the investigation of 
in vitro antimalarial activity of Artemisia afra against P. falciparum in 1993 (6). 
Crude petroleum ether soxhlet extracts from the aerial parts of the plant were 
generated and screened for activity against the chloroquine-resistant strain of P. 
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falciparum, FCR-3, in vitro. The IC50 values that were obtained ranged from 
5.4-13µg/ml. As a result, extracts of leaves and flowers were selected to be 
fractionated and purified in order to isolate and identify the active principle. It 
was also of interest to determine whether artemisinin was present in this crude 
extract and if so, to establish if it were responsible for this antimalarial effect. 
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2. Literature Review 
The following topics are discussed in this review: 
• The problem of malaria 
• The potential of plants to produce new drugs 
• The example of artemisinin in drug development 
• The potential of Anemisia afra to produce new drugs 
• Proposed strategy for the antimalarial investigation of Artemisia afra 
Malaria - the world's most common tropical disease 
Human malaria is considered to be the world's most common tropical disease 
(7). It is a key problem in public health care with respect to both morbidity and 
mortality. Present! y, there is a rapid increase in the resistance of malaria 
parasites, in particular Plasmodium falciparum, to existing antimalarial drugs. 
Over 400 million people are estimated to be affected annually. At least 2.7 
million deaths occur each year (8) of which 1-2 million are children between the 
ages of 1 and 5 (9, 10). The World Health Organization (WHO) estimate that 
85 % of the acute and chronic infections of malaria each year are caused by 
Plasmodium Jalciparum (11). In sub-Saharan Africa alone, P. falciparum is 
responsible for at least 90% of world-wide morbidity and mortality (12). The 
other 3 species of Plasmodium known to cause human malaria are P. vivax, P. 
malariae and P. ovale (in decreasing order of importance). 
Transmission and life cycle of Plasmodium 
The complex life cycle of Plasmodium comprises four phases. The first phase is 
sexual but without multiplication. The following three phases are asexual with 
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multiplication. The sexual and first asexual phases occur only in female 
Anopheles mosquitoes. The second asexual phase occurs in the liver of an 
infected human (hepatic schizogony) and the third asexual phase takes place in 
the blood (erythrocytic schizogony) of the infected individual. The third phase 
can be repeated many times. Each phase ends when new invasive parasites 
appear (13). During the erythrocytic stage, differentiation occurs for some 
parasites, specifically the merozoites into male and female gametocytes or sex 
cells which do not develop further unless another female Anopheles mosquito 
feeds on the infected blood. Thus, the sexual phase of the life cycle of the 
malaria parasite takes place in the gut of the mosquito which results in the 
release of sporozoites (14). As soon as these sporozoites enter the bloodstream 
they pass quickly to the liver where they proliferate and sporulate for the next 7-
10 days. No symptoms are experienced during this time. Parasites released from 
the hepatocytes, called merozoites, will invade erythrocytes. The merozoites 
soon develop into trophozoites which reproduce asexually to form schizonts. 
From these schizonts as many as 16-24 new parasites or merozoites are released 
which will infect more erythrocytes or red blood cells. As this cycle is repeated, 
fever is experienced each time merozoites are released (13). 
The lethal form of malaria 
Malaria caused by P. falciparum is called severe falciparum malaria or cerebral 
malaria which is a much more serious and progressive illness. It occurs in non-
immune people such as travellers and in inhabitants of areas where epidemics of 
malaria break out from time to time. Irregular tertian fever (i.e. fever every 
alternate day) is experienced at first and then there is rapid deterioration of the 
patient into stupor, fits and coma (13). From coma, the end result is usually 
death, especially if the patient is not treated timeously. 
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Partial immunity 
Adults in endemic areas, 1.e. indigenous people are protected by a form of 
partial immunity called premunition (13). Immunity develops slowly and to a 
specific species of Plasmodium only in response to repeated infections of that 
species. Partial immunity is lost if there is no longer continuous exposure to 
infection (13). In such individuals parasites are commonly found in their blood 
without the experience of symptoms. This is known as asymptomatic 
parasitaemia. 
Drug resistance 
Drug resistance of malaria parasites has been defined as 'the ability of a parasite 
strain to multiply or to survive in the presence of concentrations of a drug that 
normally destroy parasites of the same species or prevent their multiplication' 
(2). This definition has been further qualified into relative resistance, i.e. 
yielding to increased doses of the drug tolerated by the host, or complete 
resistance, i.e. withstanding maximum doses tolerated by the host. Today, the 
common use of the term drug resistance relates to complete resistance and is 
based on parasitological features (2). 
In the 1950s, it was thought that malaria would be completely eradicated with 
the use of synthetic drugs such as chloroquine, primaquine and pyrimethamine 
and with the use of DDT and other insecticides against the Anopheles mosquito 
vector (14, 15). However, resistance to chloroquine by Plasmodium was 
recognized by 1960 (14) and has since worsened. Chloroquine resistant strains 
of Plasmodium have been confirmed in at least 73 countries (2). In South 
Africa, it was first reported in 1985 (16). This is not necessarily surprising since 
chloroquine has been used in increasing quantities over the last 40 years. 
Resistance has now been reported against mefloquine and pyrimethamine (17) 
and under laboratory conditions it is possible to produce resistance against 
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artemisinin, the Chinese antimalarial (11, 14). Resistance to sulphonamide-
pyrimethamine combinations is widespread in South-east Asia, western Oceania 
and South America, and it is on the increase in Central, East and West Africa. 
In the Thai/Cambodia and Thai/Myanmar border areas resistance to quinine and 
mefloquine has become a major problem (18). No drug resistance however, has 
been reported in P. ovale and P. malariae (18). It would appear that resistance 
to new drugs is likely, unless the use of these drugs are strictly controlled (i.e. 
there is rational use of these drugs). In addition, there is also increasing 
resistance of the vector mosquitoes to DDT and other insecticides (14). 
The vector 
Only mosquitoes of the genus Anopheles are able to transmit malaria to humans. 
The mosquito vector is said to be the greatest single source of variation in the 
epidemiology of malaria worldwide (19). In most malaria endemic areas the 
parasites are often transmitted by more than one species of mosquitoes. These 
species vary greatly in terms of their numbers, feeding habits and ability to 
transmit the parasite. So not all species of Anopheles are vectors and among 
those species known to be vectors, not all of their populations are involved, and 
among the vector populations not all the individual mosquitoes are infected with 
Plasmodium (19). This is a major factor to consider in biological control 
schemes. Biological control schemes have thus far failed to make a significant 
impact on mosquito populations or the diseases they transmit (8, 19). The 
primary vector in sub-Saharan Africa is A. gambiae which is responsible for the 
high levels of human morbidity and mortality (19). 
Traditional medicine and plants 
Plants have formed the basis for the treatment of diseases throughout the ages 
and continue to be a major source of primary health care for about 80% of the 
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world's population, as estimated by the WHO (20). Sophisticated plant-based 
traditional medicine systems have been in existence for thousands of years in 
countries such as China and India. Medicinal plants are also used extensively in 
African traditional health systems (21). The first African pharmacopoeia under 
the auspices of the Organization of African Unity's Scientific and Technical 
Research Commission was released in 1985 (first volume) and 1986 (second 
volume). The first volume describes about 100 common medicinal plants and 
specifies the standards to be used in their quality control. The second volume 
describes the methods to be used in the quality control of these herbs (22). 
Numerous phytomedicines are registered and are extensively used in Europe. 
More than 600 botanical items have been officially recognized in various 
editions of the United States Pharmacopoeia even though current regulations 
prohibit most from being marketed as drugs. In Australia the traditional 
therapeutic use of native plants by the indigenous people was not recorded in a 
written format. The extent of their knowledge is only now becoming apparent 
(21). 
The potential of plants to produce new drugs 
In developed countries, which make up 20% of the world's population, more 
than 50% of all the drugs in clinical use are of natural product origin. Of the 25 
best selling pharmaceutical agents in the world, 12 are natural product derived 
(21). It has also been reported that there are 119 drugs of known structure that 
are still being extracted from higher plants and are being used globally (20). Of 
these 119 plant-derived drugs, 74% were discovered as a result of chemical 
studies specifically designed to isolate the active principles responsible for the 
use of the plants in traditional medicine. These drugs were derived from only 
about 90 of the 250 000 known species of flowering plants throughout the world 
(20). Less than 10% of the estimated 250 000 flowering species in the world 
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have in fact, been examined scientifically for their potential in medicine. It is 
estimated that by the year 2050, 60 000 species of higher plants (i.e. 1 out of 
every 4 plants) will have become extinct (23). Sadly, there is little time 
remaining to explore this rapidly diminishing resource. Throughout the 
developing world there are more than 20 000 species of higher plants which are 
used in traditional medicines (24,25) and these together with the other 230 000 
species of higher plants, form a vast reservoir of potential for new drugs. 
Traditional medicines in South Africa 
There is a genuine and increased interest in traditional medicine developing in 
South Africa. There is an increase too, in the understanding of and acceptance 
of practitioners of traditional, indigenous and alternative systems of medicine. 
There are an estimated 200 000 traditional healers (26) in a total population of 
about 45 million in South Africa. As many as 12 000 healers are known to be 
present in Soweto alone (27). Almost 75-80% of black South Africans consult 
these healers, often in addition to using western medicines (26,28). Medicinal 
plants are used extensively by these healers and are also commonly used by the 
public for self care. These medicines are generally used in a crude form. They 
are harvested from the wild by rural communities, traditional healers and 
professional herb gatherers. Approximately 3 000 plant species are being used 
as medicines, probably, because of South Africa's rich biodiversity. About 350 
species are recognized to be commonly used and are traded throughout the 
country (26). In a recent survey, more than 500 species were found to be 
harvested and traded as medicinal plants in the Witwatersrand alone. Most of 
these were being sold as bark and roots, although the leaves, stems, whole 
plants and bulbs are also sold. The most commonly stocked plant was Artemisia 
afra, followed by Scilla natalensis, Thesium pallidum and Knowltonia bracteata 
(27). 
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Research performed in South Africa 
In South Africa, Noristan Ltd. began a systematic natural product research 
project in 1974, with the aim of isolating and identifying pharmacologically 
useful compounds from the diverse and rich Southern African flora. South 
Africa alone has 24 000 species of flora. The success of their project has indeed 
been very encouraging. From a total of about 300 plants evaluated, 81 % showed 
biological activity (29). 
Advances in technology 
Over the past three decades, there has been an enormous improvement in 
techniques for the isolation and structure determination of plant constituents. 
New, sensitive and sophisticated chromatographic techniques such as TLC, GLC 
and HPLC are being used for separation and isolation procedures and X-ray 
crystallography and spectroscopic techniques such as UV, IR, CD, 1H and 13C 
NMR are used for structure elucidation (25). 
Until recently, gram quantities of a pure compound were required to undertake 
whole or isolated organ experiments in order to establish pharmacological 
activity. Now with the development of modern pharmacological assays that are 
highly sensitive and specific, minute amounts of compounds can be rapidly 
screened for a whole series of biological activities (25) and their structures 
determined (30). Industry has also established automated high throughput in 
vitro screens for biological activities which are capable of examining thousands 
of compounds or extracts in very short periods of time. In the field of malaria 
research, continuous in vitro culture of P. falciparum was not achieved until 
1976 (31) and the first in vitro antimalarial screening assay was only made 
possible in 1979 by Desjardins et al. (32) where drug effects were monitored by 
the measurement of radiolabelled hypoxanthine incorporation into parasite 
nucleic acids. Hence, there is a race to locate new drug entities from natural 
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sources. Never before has there been such an opportunity for collaborative 
research amongst botanists, chemists, pharmacognosists, pharmacologists and 
toxicologists to isolate and produce novel drugs. 
As a result of these new technologies it has become current fashion to use 
bioactive-guided fractionation of plant extracts in attempts to isolate biologically 
active compounds (25). Such studies offer a logical approach for new drug 
discovery and for the identification of template molecules for the design of new 
drug molecules (24). For example, morphine from the opium poppy, used as a 
highly effective analgesic for the relief of terminal pain, had served as a 
template molecule for the design of numerous drugs including analgesics such as 
pethidine and pentazocine and the cough suppressant dextromethorphan. 
Similarly, tubocurarine from Chondrodendron tomeniosum is the potent muscle 
relaxant of tube curare which has served as a template molecule for a number of 
synthetic analogues such as decamethonium, suxamethonium, pancuronium and 
more recently, atracurium (24). 
During the past 25 years only a few drugs from higher plants have yielded 
clinical agents. The outstanding examples are taxol derived from Taxus 
brevifolia (the Pacific yew tree) (34), vinblastine and vincristine from the 
Madagascan periwinkle, Catharanthus roseus and etoposide, the semi-synthetic 
lignan from the May-apple Podophyllum peltatum (24). The isolation of 
artemisinin from Artemisia annua has once again focused on higher plants as 
potential sources of new drugs. 
Scientific verification of plant use 
The WHO estimate that 80% of the world population reside in developing 
countries and that 80% of these people use traditional medicines, which includes 
medicinal plants for their primary health care needs. This means that there are 
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more than 3.2 million people in the world who are currently using extracts of 
plants as drugs. Most of these plants have not been verified scientifically as 
being useful for the conditions that they are being used for (20). 
Thus, another important reason for studying the use of medicinal plants is to 
validate scientifically their effects and side-effects so that they can be 
recommended for use in developing countries where they are culturally 
acceptable and provide cost-effective medicines (20). 
The ethnobotanical approach 
The pharmacology of herbal plants involves a number of disciplines. The study 
of the use of plants by various cultures is called ethnobotany. The study of how 
a culture uses herbs therapeutically is a branch of ethnomedicine. The study of 
the active principles in these plants is ethnopharmacology. In general, the 
chemistry, pharmacology and toxicology of even widely used plants have been 
poorly studied (33). The ethnobotanical approach to drug discovery (i.e. if a 
plant has been used by indigenous cultures over a long period of time, there 
should be valid drug potential in the plant), is likely to yield greater success than 
random screening of plants (33,34). The discovery of taxol is one notable 
exception. It was discovered in a random screening programme conducted by 
the National Cancer Institute (NCI). Taxol derived from Taxus brevifolia (the 
Pacific yew tree), was approved by the FDA (Food and Drug Administration) 
for the treatment of ovarian cancer and in 1994 it was approved for treating 
metastatic breast cancer unresponsive to any other therapy (34). 
Food for pharmacological thought 
Attention has to be drawn to the use of plant foods as a means of maintaining 
health. For example, the anti-inflammatory and antimicrobial effects of onion 
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(Allium cepa L.), garlic (Allium sativum L.), basil (Ocimum basilicum L.), 
fennel (Foeniculum vulgare Mill.) and ginger (Zingiber officinale Rose.) are 
well known. Such foods may be used in small quantities but frequency of 
consumption may ensure sufficient exposure to effect both preventative and 
therapeutic action against illness (35). 
The processing of some foods may involve grating, alkaline treatment and high 
temperature cooking in water or milk. Such treatment not only softens and 
renders the food more palatable but also increases the solubility of the plant 
constituents considerably which might only have been marginally available from 
medicines prepared with coarsely cut materials infused in small volumes of 
water, and particularly when medicines are prepared quickly for immediate use 
(35). 
Thirdly, just as modem medicine recognizes both beneficial and adverse 
interactions between drugs and food, so too, combinations may influence 
physiological effects of plants. For example, synergistic and potentiating 
interactions occur between digitalis and high calcium foods, and among alcohol 
containing foods, interactions occur between metronidazole and narcotic drugs. 
Antagonism occurs between tetracyclines and high calcium or iron-rich foods. 
Similarly, in plant mixtures the oxytocic and vasopressive activities of serotonin 
and tyramine (e.g. in Gossypium hirsutum L., Cystisus scoparius (L.) Link and 
Phoradadendron serotinium (Rat) MC Johnst.) are protected by monoamine 
oxidase inhibitors such as myristicin and its congeners in, for example, dill, 
parsnips and parsley (Athenum graveolens L., Pastinaca sativa L., and 
Petroselinum crispum (Mill) Nym.). 
In Nigeria, studies of Hausa medicine have shown a mutually complementary 
relationship between diet and medicine. Many of the Hausa plants contain 
substantial amounts of phytates (especially in cereals and legumes) and tannins 
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(in most ligneous species) which serve as chelators and may have the potential 
to suppress the effect of malaria by sequestering iron. This action may be 
further potentiated by the oxidising action of other Hausa foods and medicines 
such as Cassia tora L., C. occidentalis L. (also recorded in the PHARMEL 
database; used in the treatment of malaria), Guiera senegalensis Lam., and 
Acacia arabica Willd. Alternatively, the antimalarial effect may be antagonised 
by antioxidants such as vitamins C and E, P-carotene and selenium which are 
major radical traps and which occur in high concentrations in some of the same 
plants such as tea leaf, Camellia sinensis (L.) Kuntze; tumeric, Curcuma long a 
L.; date palm, seed Phoenix dactylifera L.; Tribulus terrestris L.; Amaranthus 
viridis L.; Amaranthus spinosus L.; Solanum nigrum L.; Euphorbia hirta; 
Moringa oleifera Lam. Studies of a Hausa village noted high consumption of 
both foods and medicine that have antiplasmodial potential during the malaria 
season (35). 
New antimalarials with novel modes of action 
Since there are no effective vaccines and still no sign of a vaccine in the near 
future, new chemotherapeutic agents or antimalarial drugs, preferably with 
novel modes of action against Plasmodium are urgently being sought. 
Chemotherapy often produces serious adverse side effects e.g. FansidarR 
(pyrimethamine and sulphadoxine) may cause epidermal necrosis (14). Since 
traditional plants may provide a rich source of potential antimalarial drugs it 
made good sense to investigate medicinal plant preparations used by local 
traditional healers for symptoms of malaria. Plants may directly provide new 
antimalarials e.g. quinine from Cinchona bark. Alternatively, they could 
provide template molecules on which to base synthesis of further novel 
structures. Quinine led to the development of synthetic drugs such as 
chloroquine, amodiaquine, primaquine and more recently, mefloquine (14,36). 
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Fig. 1: Chemical structures of some antimalarial drugs in clinical use. 
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Artemisinin - the Chinese antimalarial 
In China herbal medicines are as important as synthetic drugs and account for 
30-50% of the total consumption of drugs (11,37). An extensive search for new 
antimalarials from traditional sources in China which started in 1967 led to the 
isolation of an active antimalarial fraction from Anemisia annua L. (sweet 
wormwood) (Asteraceae) in 1971. The active compound, Qinghaosu or 
Artemisinin was isolated and its structure was determined the following year 
(3,38). Qinghaosu literally means "extract of qinghao (green herb)". The herb 
has been used for more than 2 000 years as an antipyretic and for symptoms of 
malaria (3, 11). The plant is widely distributed in Europe, North America, India 
and Eastern Asia (38). 
Artemisinin and its derivatives 
Artemisinin or Qinghaosu is a sesquiterpene lactone peroxide which belongs to a 
new class of antimalarials called the endoperoxides. Artemisinin is structurally 
different from other known antimalarial drugs (Fig. 2). It is not water-soluble, 
but decomposes in a number of protic solvents, which probably cause the 
lactone ring to open. The compound is stable in aprotic solvents up to 150°C 
(3). The unusual endoperoxide moiety appears to be essential for antimalarial 
activity because derivatives that lack the endoperoxide ring do not have 
antimalarial activity. Substitutions at the lactone carbonyl group results in an 
increase in potency (3,38,39). 
The first-generation endoperoxides 
Dihydroartemisinin, a borohydride-reduction product of artemisinin, is more 
potent than artemisinin (3). This compound was converted into a number of 
ether derivatives, namely, artemether (methyl ether of dihydroartemisinin) and 







Na+ artesunate OCO(CH2) 2C00Na 
Na• artelinate OCH,-0- COONa 
Fig. 2: Chemical structure of artemisinin and its derivatives. 
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These derivatives represent the first generation endoperoxides. Artemether was 
initially prepared for intramuscular injection but it can now be taken orally too 
(4). Artmether injection (PalutherR) is registered in Brazil, China, Burma, 
Thailand and in at least 9 African countries (40). Capsules are also produced. 
Phase II trials in adult patients with non-severe multidrug resistant falciparum 
malaria were completed in 1995 and the results are likely to be published soon. 
Meanwhile, clinical trials of intramuscular formulations in patients with severe 
falciparum malaria were initiated in 1995 and will continue for about 2 years 
(40). Artesunate tablets and injection are registered in Brazil, China, Ghana, 
Burma, Thailand and Vietnam (40). An oral formulation of sodium artelinate 
was found to be as effective as artesunate (40,41). Other derivatives included 
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carboxylic esters, carbonates and sulfonates. Carbonates are the most potent, 
followed by esters, ethers, and then artemisinin (3, 11). 
The second-generation endoperoxides 
The total stereoselective synthesis of artemisinin has made it possible to 
synthesize the artemisinin derivatives other than the ethers or esters of the 
dihydroartemisinin lactol. The second generation endoperoxides are synthetic 
compounds. Literally hundreds have been synthesized. Many resemble 
artemisinin but others such as the trioxanes and tetraoxanes do not ( 40). 
Cultivation 
Only A. annua and A. apiacea have so far been reported to contain artemisinin 
(38). Artemisinin was either lacking or only found in trace amounts in about 
100 other species of Artemisia (42). Artemisinin is obtained from the leaves of 
A. annua. Its yield is variable and it depends on a number of factors such as 
plant strain, stage of development, environmental and soil conditions. Maximum 
yields of artemisinin from cultivated Artemisia are about 2 % of plant dry weight 
whereas, values in the wild are usually 0.01-0.5% (38,43) but higher 
concentrations have been reported from Chinese clones ( 44). The highest 
content is either just before flowering (38,45) or in the inflorescence itself at 
anthesis (42). In Vietnamese plants however, the highest possible yield of 
artemisinin was found at the early developmental stages i.e. 5 month old plants 
(46). This was probably as a result of the tropical climate which meant that the 
vegetation period of A. annua is longer th~ in countries with moderate 
climates. Therefore, plants can be harvested twice, instead of once a year. 
Drugs in current use are all derived from cultivated A. annua. 
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Plant biotechnology 
Because chemical synthesis of artemisinin is complicated (although possible) and 
has provided poor yields, the plant remains the only viable source of supply for 
artemisinin and the subsequent synthesis of its derivatives (46,47). Numerous 
laboratories are therefore searching for strains of A. annua that contain the 
highest levels of artemisinin. Experiments have so far included field grown 
plants, plants grown in greenhouses, and tissue-cultured plants 
(42,43,44,46,47). A Chinese clone has been reported to produce more than 1 % 
artemisinin which is considerably greater than the general range of 0.01-0.50% 
(44). 
Antimalarial activity 
Dihydroartemisinin, artemether and artesunate, first developed in China have 
been used to treat P. falciparum and P. vivax infections in countries such as 
China, Vietnam, Burma, Thailand, Gambia and Kenya (4). These corupounds 
are particularly useful for the treatment of severe malaria. They are the most 
rapidly acting of all the antimalarials and have the broadest stage specificity 
(asexual and sexual) of antimalarial action. In contrast, quinine, chloroquine, 
hydroxychloroquine, amodiaquine and quinacrine, chlorguanide and 
pyrimethamine, sulfonamides and sulfones are sensitive only to the asexual 
erythrocytic stages ( 48). Primaquine is effective against the sexual erythrocytic 
stage (gametocidal) (48). Artemisinin and its derivatives produce a more rapid 
clinical and parasitological response as well as reduce fever more quickly than 
any of the other antimalarial drugs (38,49). 
Pharmacological experiments have shown that artemisinin and its derivatives 
affect the erythrocytic stages of Plasmodium in nanomolar concentrations 
(45,50). The drugs have fast schizonticidal action (11). Clearance of parasitemia 
is achieved within 24 hours. The mature stages of the schizonts of P. falciparum 
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were found to be more susceptible to the drugs than the ring stages ( 11). In 
contrast to these findings, ter Kuile and co-workers found that the maximum 
effect of artemisinin and sodium artelinate was against the late ring and early 
trophozoite. Antimalarial action was rapid after a lag phase of 1-4 hours (51). 
The drug is also reported to have gametocidal activity which could be important 
for blocking transmission of the disease (45,49). The drug unfortunately cannot 
be used for prophylaxis because of its short half-life. It also lacks sporontocidal 
activity i.e. activity against the mosquito-stage sporozoites and causal 
prophylactic activity i.e. activity against the pre-erythrocytic stages. 
Hypnozoitocidal activity is also absent i.e. inactive against the liver stages of the 
parasite (49). 
Resistance 
Artemisinin and its derivatives are effective against Plasmodium species that 
have developed resistance to other antimalarial drugs, both in vitro and in vivo 
(11). They have not demonstrated any cross resistance with chloroquine in drug-
sensitive and drug-resistant strains of P. falciparum in vitro (11). Although there 
is cross resistance of artemisinin with chloroquine in mice infected with P. 
berghei (11) to date, there is no cross resistance with other currently used 
antimalarial drugs (49). Interestingly, in a multidrug-resistant strain of P. 
falciparum, synergism has been found between arteether and mefloquine or 
quinine in vitro ( 45). 
The mechanism of drug resistance is not clearly understood. It is clear that P. 
falciparum parasites that are resistant to chloroquine concentrate less drug in the 
food vacuole than do sensitive parasites which seems to suggest that the mode of 
action of the drug is independent of the mechanism of resistance (52). 
Decreased accumulation of chloroquine in resistant parasites could occur by two 
mechanisms: firstly, efflux of the drug from the food vacuole and secondly, 
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alterations that reduce the uptake of the drug in the parasite. There is also the 
possibility that both mechanisms could be operating together (52). 
Pharmacokinetics and drug metabolism 
Pharmacokinetic studies have been hampered by difficulties encountered in 
developing a reproducible assay for the parent drug and its metabolites even 
though a variety of methods such as HPLC using an electrochemical detector 
(53), packed-column supercritical fluid chromatography with electron-capture 
detection (54), and more recently HPLC with chemiluminescence detection 
(55), radioimmunoassay (RIA) and enzyme-linked immunosorbent assay 
(ELISA) (56) are also available. It is hoped that the most recent attainment of 
the stereoselective total synthesis of radiolabelled (deuterated) artemisinin, 
dihydroartemisinin and arteether (57), will boost further studies into the 
pharmacokinetics and drug metabolism of this class of drugs. 
Oral administration of artemisinin leads to low plasma levels of drug and rapid 
first pass metabolism to inactivate metabolites. However, the derivatives are 
hydrolysed mainly to the active derivative, dihydroartemisinin and to other more 
hydrophilic metabolites. Intramuscular and intravenous administration improves 
drug plasma levels and drug efficacy (49). 
Artemisinin and its derivatives bind avidly and irreversibly to membranes 
including to those of normal erythrocytes. They may also bind covalently to 
plasma proteins. In plasma, arteether binds both to albumin and to ai-acid 
glycoprotein. Binding is 20-fold greater for the glycoprotein. In plasma about 
75% of the drug is bound. Intravenous artesunate is cleared very rapidly by 
biotransformation and is eliminated with a half-life of 45 minutes (38). 
Artemisinin is rapidly distributed in the tissues; it passes the erythocytic wall, 
the blood-brain barrier, the salivary glands and the placenta (45). 
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Recrudescence 
The one major disadvantage of the artemisinin derivatives is the high rate of 
recrudescence i.e. recurrence of the disease after a brief intermission period 
(3,38). Recrudescence is greater than 10% which is unacceptably high (40). 
Interestingly, there are lower recrudescent rates reported when the artemisinin 
derivatives are combined with other antimalarial drugs, in particular 
mefloquine. As mentioned earlier, the artemisinin derivatives and mefloquine 
have been reported to be synergistic both in vitro and in vivo ( 49). The 
combination of artesunate and artemether with mefloquine in the treatment of 
falciparum malaria has substantially improved efficacy. Cure rates for 3-5 days 
of combined treatment still exceeds 85 % even though the sensitivity to 
mefloquine is expected to continue to decline (58). 
Mechanism of action 
Changes of the ultrastructure of parasite membranes after exposure to the drug 
have been described. Meano et al. (59) reported ultrastructure changes induced 
by P. falciparum in vitro by artemisinin and dihydroartemisinin. The drugs 
accumulated in the food vacuole and mitochondria. An additional incubation 
period of 2-4 hours revealed changes in the parasite mitochondria, rough 
endoplasmic reticulum, nuclear envelope, nuclear and plasma membranes. 
There was also a disappearance of ribosomes and destruction of the food vacuole 
membranes (11,45,49). Artemisinin and its derivatives have also been shown to 
have the following effects in malaria parasites: membrane damage, alkylation 
and oxidation of proteins, oxidation of fats, inhibition of protein and nucleic 
acid synthesis as well as interaction with cytochrome oxidase and the glutamine 
transport system (45). 
Since Plasmodium decompose host-cell haemoglobin to obtain essential amino 
acids in the food vacuole, it was suggested that artemisinin reacts with 
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haemozoin, thereby causing antimalarial activity. Evidence to support this 
hypothesis came from an in vitro experiment that demonstrated a reaction 
between haemozoin and artemisinin (39). Intraparasitic haeme-activated 
artemisinin irreversibly decomposed to generate free radicals that alkylate and 
oxidise proteins (haemozoin) and lipids (38,39). Since the action of these 
compounds are potentiated by oxygen and oxidant drugs such as miconazole and 
doxorubicin (and attenuated by reducing agents such as catalase, dithiothreitol 
and a-tocopherol) (3,45), the oxidative stress already imposed by the parasite on 
its erythrocyte host is augmented and surface recognition signals are presumably 
enhanced (38). This serves to promote cytotoxicity, phagocytosis and clearance 
by the host leucocytes (38). It was also found that when P. falciparum infected 
red blood cells were exposed to radiolabelled artemisinin, it was possible to 
isolate a haem-artemisinin adduct. It was suggested that the same occurs in situ. 
No such adduct was isolated when uninfected red blood cells were exposed to 
radiolabelled drug. This suggests that the drug does not react with haemoglobin-
bound haemozoin. It could also account for the selective toxicity of the drug to 
the parasites (39). Further evidence for the role of haemozoin comes from an in 
vivo experiment of a chloroquine-resistant P. berghei strain which lacked 
haemozoin. Artemisinin was found to be more than 50 times less effective 
against the strain which indicated that the parasites were insensitive to the drug 
(39). 
Furthermore, it has been suggested that the antimalarial activity of artemisinin 
in animal cell cultures is associated with the dramatic reduction in the 
concentration of polyamine putrescine (45). Antimalarial activity has been 
shown not to be mediated via intercalation with nucleotides as is the case of the 
aminoquinoline-type antimalarials (40,45). 
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Artemisinin and its derivatives have now been shown to affect parasites very 
differently from other oxidant drugs. Instead of reacting with oxygen and 
producing large quantities of oxygen-containing free radicals such as superoxide 
and OH
0
, artemisinin itself, becomes a free radical in a reaction catalysed by 
iron ( 40). In vitro, it was found that haem and iron catalyse the conversion of 
artemisinin and its derivatives into free radicals in a manner similar to the way 
that they catalyse the decomposition of hydrogen peroxide into free radicals. 
Using cyclic voltammetry it was shown that haem caused a 0.6-V shift in the 
reduction potential of artemisinin, which indicates that haem accelerates the 
decomposition of artemisinin by several orders of magnitude (39). The iron-
catalysed generation of a free radical from artemisinin was confirmed by 
electron paramagnetic resonance spectroscopy and by studies of isolated 
erythrocyte membrane (40). The mechanism of iron-mediated decomposition of 
artemisinin and its derivatives in vitro has been determined by the structural 
elucidation of the decomposition products and by mechanistic studies on their 
rates of formation. The reductive cleavage of the endoperoxide bridge involves 
the transfer of an electron from ferrous iron (i.e. Fe[II]) and the formation of 
Fe[IV] =0 (60). The endoperoxide bridge is cleaved first and then there is 
intramolecular electronic rearrangements which produce carbon-centred radicals. 
These carbon-centred radicals are important because artemisinin derivatives that 
do not form such radicals have no biological activity (40). 
In summary, artemisinin and its derivatives are thought to exhibit a two step 
mode of action as proposed by Meshnick et al. (40,61). In the first step, 
artemisinin compounds are activated by haem or molecular iron to produce free 
radicals and electrophilic (alkylating) intermediates. In the second step, these 
reactive species react with and damage specific malaria membrane-associated 
proteins. Therefore, artemisinin derivatives are free radical generators. The 
resulting free radicals are however, carbon-centred. There are also specific 
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target proteins that are involved (40,61). Elucidation and identification of these 
target proteins are yet to be achieved. 
Toxicity 
From the available literature, artemisinin is remarkably non-toxic even at high 
doses (45). In a study by Meshnick et al. (45) mice were not adversely affected 
with doses as high as 2g/kg body weight. The therapeutic dose of artemisinin in 
mice is about 4mg/kg. In monkeys however, high doses have been shown to 
cause inhibition of haematopoiesis, as well as cardiac, renal and hepatic toxicity 
(45). In dogs and rats a selective and dose-related neurotoxicity in the central 
nervous system and mid-brain had been found (45). There is also toxicity 
reported of artemisinin derivatives to neuronal cells in vitro where protein 
synthesis is inhibited (62). 
In humans, no significant toxicity has been reported. This is in stark contrast to 
the quinoline antimalarials. In clinical studies of over 4 000 patients there is no 
evidence of toxicity (38). However, it has been suggested that there is a 
possibility of cumulative toxicity due to a long-lived toxic metabolite, especially 
if the drugs are misused when given as prophylaxis or when patients are treated 
frequently (38). The China Cooperative Research Group on Qinghaosu and Its 
Derivatives as Antimalarials has stated that the artemisinin drugs can be safely 
used for malaria patients with cardiac, hepatic or renal disorders (11). 
Distribution of Arlemisia 
The genus Artemisia (Asteraceae, previously Compositae) with more than 500 
species, including the sometimes separated genus Seriphidium (63) is very 
widely distributed. It is predominantly found in the northern temperate regions 
of the world (i.e. North America, Europe, Asia and North Africa) with a 
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southward extension towards the tropics. A. afra grows at an altitude of 2 400m 
in Tanzania, Kenya and South Africa. The following Artemisia oils are 
commercially available: A. absinthium (wormwood); A. annua; A. pa/lens 
(davana oil) used to flavour tobacco; A. dracunculus (tarragon) used as a herb in 
cooking; and A. herba alba (armoise) which is used in the perfumery industry 
(64). A. absinthium was used until the 1920s to prepare the narcotic and now 
illegal (due to its neurotoxicity) drink called absinthe (3). 
Reasons for investigating A. afra 
Since A. afra is commonly used by traditional healers for symptoms and 
treatment of malaria, and because it belongs to the same family as A. annua, 
from which artemisinin was isolated (chemotaxanomic approach), it seemed 
appropriate that the South African variety be investigated for antimalarial 
activity. Furthermore, the Tanzanian variety demonstrated antimalarial activity 
with IC50 values of 10-49µg/ml but the active compound has as yet, not been 
identified (65). Also, although there have been a number of phytochemical 
studies conducted on A. afra (66,67,68) none of the isolated compounds had 
been screened for antimalarial activity. 
Anemisia afro 
A. afra Jacq. (African wormwood) is a bushy branched perennial shrub that 
grows up to 1 metre (68). It is the only species of Artemisia that occurs in South 
Africa (67). The plant can be found throughout the Amatola and Drakensberg 
mountain regions of South Africa. It can be propagated from seeds, cuttings and 
root pieces. Its grey-green leaves are aromatic when crushed and its essential oil 
has a similar fragrance to armoise. Other names for the plant include: wildeals 
(Afrikaans); lengana (Tswana); zengana (Southern Sotho); umhlonyane (Xhosa); 
and mhlonyane (Zulu). 
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Medicinal properties 
A. afra is one of the most widely used medicinal plants in Southern Africa. It is 
applied to a large range of illnesses, which include the common cold, diabetes 
mellitus, respiratory complaints and gastric intestinal tract disorders, toothache 
and earache. The leaves are used as a tea, for a bath, as a leaf poultice or 
vapours from boiling leaves can be inhaled. It is also used as an insect repellant 
and as an antithelmintic (5,69). The essential oils of A. afra were shown to 
exhibit antibacterial, antifungal and anti-oxidant properties (68). 
Toxicity 
There has been only one toxicity experiment on the essential oil of A. afra, 
performed on rabbits (oral administration) which resulted in haemorrhagic 
nephritis, degenerative change in the liver and pulmonary oedema (5). These 
results may not necessarily be reflected in humans. Since the registration of the 
essential oil of A. afra, there have been no reports of toxicity and neither can 
any reports be found on toxicity of the plant when used medicinally in humans. 
Proposed strategy for the investigation of A. afra 
The proposed strategy for the antimalarial investigation of A. afra was adopted 
from a similar strategy reported by Hamburger and Hostettmann (70). The 
following steps were involved: 
(i) positive identification of the plant by a botanist, collection and drying of 
the plant material; 
(ii) preparation of crude extracts and preliminary chromatographic analysis 
by TLC; 
(iii) bioassay of crude extracts; 
(iv) several consecutive steps of chromatographic separation with each 
fraction obtained submitted for bioassay in order to follow the activity; 
(v) verification of the purity and activity of the isolated compounds; 
(vi) structure elucidation of isolated pure compounds; 
(vii) toxicological testing of isolated pure compounds. 
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As mentioned earlier, medicinal plant research requires a multidisciplinary 
approach. Although the search process for pharmacologically active compounds 
from plants is very long, the benefits (economic, cultural and social) to be 
derived therefrom, are enormous. 
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3. Aims and Objectives 
Aim 
To fractionate a crude extract of Artemisia afra that has demonstrated 
antimalarial activity in vitro against Plasmodium falciparum in order to purify 
and identify the active antimalarial compound(s). 
Objectives 
1. Purification of A. afra crude extract in order to identify the active 
compound(s). 
2. To compare antimalarial activity in vitro of the purified compound(s) 
against a variety of strains of P. falciparum which have varying degrees 
of sensitivity and resistance to both chloroquine and mefloquine. 
3. To determine whether or not extracts of A. afra contain artemisinin. 
4. To distinguish general cytotoxic properties of the compound(s) from in 
vitro antimalarial activity against P. falciparum using the MTI assay. 
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4. Methods 
4.1. Plant material 
Anemisia afra Jacq. was collected from the National Botanical Gardens 
(Kirstenbosch) in Cape Town. The aerial parts of the plant which were 
harvested on two occasions in 1996 were allowed to air-dry at room temperature 
away from direct sunlight. The first harvest took place in January before the 
flowering season. The second harvest was at the end of the flowering season and 
at the stage when seeds were developing, in May. 
The material of the crude extract which was of leaves and flowers, active in 
vitro against P. falciparum had been collected in April 1993 during the 
flowering season. 
4.2. Extraction 
Initial plant extractions for A. afra were performed in a Soxhlet apparatus 
(Appendix A) which involved heating of the solvent to high temperatures. Even 
though this method is used to extract artemisinin from A. annua (3,71) there 
was concern that there may be compounds of interest that could be heat sensitive 
and were therefore, being degraded. As a result, cold extractions with 
dichloromethane and water at room temperature were also performed. 
Dried aerial parts of A. afra were divided into 3 batches. The first batch was 
continuously extracted with petroleum ether (b.p. 40-60°C) in a Soxhlet 
apparatus for 21 hours. The second batch was exhaustively extracted at room 
temperature in dichloromethane for 24 hours at a time. The third batch was 
extracted in distilled water for 3 x 24 hours, also at room temperature. 
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A sample of A. afra collected during the flowering season was continuously 
extracted with distilled water in a Soxhlet for up to 28 hours so that it could be 
compared to the cold water extract. 
The crude extract prepared in 1993 which was of leaves and flowers had also 
been extracted with petroleum ether (b.p. 60-80°C) in a Soxhlet for 14 hours. 
The extracts obtained were clarified by filtration and then concentrated in vacuo 
in a rotary evaporator (Buchi 461). Water extracts were dried in a freeze drier 
(Virtis Company Inc.). All the extracts were stored in sealed glass vials in a 
refrigerator until needed. 
4.3. Column chromatography 
The crude extract of leaves and flowers, 4.6g, was dissolved in 20ml 
dichloromethane and heated gently before being applied to a silica gel-60 
(0.063-0.200mm) column (86.50x2.50cm). Components of the extract were 
initially eluted with 100% petroleum ether followed by petroleum ether with 
increasing amounts of ethyl acetate and finally with methanol. As fractions were 
collected they were analysed by TLC and the polarity of the solvent mixture was 
increased only when elution with a particular solvent composition was complete. 
A total of 120 fractions were collected which were then pooled on the basis of 
their TLC profiles. The resulting fractions, Pl-P9, were screened for 
antimalarial activity. 
4.4. Thin layer chromatography 
Samples were dissolved in dichloromethane and applied to TLC aluminium 
sheets pre-coated with silica gel-60 (F254) with 0.2mm layer thickness (Merck). 
Pure artemisinin (Sigma) (lmg/ml) was prepared in the same way and applied as 
a standard. The plates were dried using a hair dryer, after which they were 
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transferred to a tank containing the developing solvent system (mixtures of 
petroleum ether, dichloromethane and ethyl acetate). As soon as the plates were 
developed (± 5 minutes) the solvent front was marked and the plates were blown 
dry. To visualize the spots, the plates were immersed in an anisaldehyde stain 
reagent. Excess anisaldehyde stain was blotted off with paper towel and the 
plate was then heated gently on a hot plate until the colour reaction was 
complete. 
The anisaldehyde reagent was prepared in the following order with thorough 
cooling with liquid nitrogen before addition of glacial acetic acid and 
concentrated sulphuric acid: 6.5ml p-anisaldehyde (Riedel-de Haen) in 232ml 
95% ethanol; 2.5ml glacial acetic acid and 7.5ml concentrated sulphuric acid. 
Sulphuric acid needed to be added slowly. 
4.5. Flash Chromatography 
Fraction P6, 372mg, was chromatographed under pressure on a silica gel-60 
(230-400 mesh) column (60.0xl.7cm) to yield 5 sub-fractions labelled 1 to 5 
(Fig.3). The initial solvent composition was petroleum ether/ethyl acetate [3: l] 
and followed by petroleum ether/ethyl acetate [3:2] for complete elution of the 
sample components. 
4.6. Centrifugal Thin Layer Chromatography 
Fraction P6.2, the second sub-fraction of fraction P6, appeared to contain the 
major compound. This fraction (199mg) was chromatographed on a 
chromatotron, which is a preparative, centrifugally accelerated, radial, thin-
layer chromatograph (Appendix B). The absorbent layer containing 70g silica 
gel-60 PF254 with gypsum for preparative layer chromatography (Merck), 5g 
calcium sulphate (CaS04.'.!,af20) and 132ml H20 at 0-5°C was cast onto the 
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rotors, allowed to set (25min) and then dried overnight in an oven at 70°C 
before being scraped to 2mm thickness with a rotating scraping tool. A gradient 
solution of petroleum ether/ethyl acetate [90: 10], petroleum ether/ethyl acetate 
[80:20] and petroleum ether/ethyl acetate [60:40] was used to elute the 
compounds. Three fractions labelled A, B and C were generated, of which sub-
fraction B was the major compound. 
The second sub-fraction, P6.2B was repeatedly chromatographed on the 
chromatotron using petroleum ether with increasing amounts of ethyl acetate. A 
mixture of petroleum ether/dichloromethane/ethyl acetate [25:3: 10] was finally 
used as eluent and the fraction was then purified by flash chromatography 
(42.0xl.5cm) using the same procedure. The total yield of purified P6.2B from 
fraction P6 was 113.5mg of which 26mg was submitted for NMR analysis. Fig. 
3. below summarizes the fractionation sequence for the crude A. afra extract. 








4. 7. High pressure liquid chromatography 
Reverse-phase high pressure liquid chromatography (HPLC) (Shimadzu LC-
lOAS, Shimadzu Corp., Kyoto, Japan) linked to a diode array detector 
(Shimadzu SPD-MlOA) and two Shimadzu LC-10 AS liquid chromatographic 
pumps, a 486 DX2-50 personal computer and a Hewlett Packard Deskjet 600 
printer was performed using an analytical C18 Prodigy ODS-2 column with 
dimensions: I50x4.60mm 5 micron (Phenomenex, California USA). The 
mobile phase was a gradient of MeCN (HPLC-grade) and distilled, deionized 
water (Millipore). A guard column was used throughout experiments to retain 
particulate matter, especially from crude plant extracts. The flow rate was 
lml/min. 
HPLC profiles (45min) of artemisinin, crude A. afra extracts and the isolated 
pure compound, P6.2B, were obtained. 
4.8. Detection of artemisinin by thermospray LC-MS 
Three samples of crude A. afra extracts were sent to Prof. K. Hostettmann at 
the Institute of Pharmacognosy and Phytochemistry, University of Lausanne, 
Switzerland, for an accurate detection of artemisinin using thermospray LC-MS 
(72). The samples were: the crude petroleum ether soxhlet extract of leaves and 
flowers; the cold dichloromethane extract of leaves; and the petroleum ether 
soxhlet extract of leaves. 
Each extract (100mg) was dissolved in 1ml of a THF/MeOH (50:50) solution of 
which 10µ1 was injected onto the HPLC. Effectively, 1mg of extract was 
injected onto the column. 
The crude extracts were separated on a C18 column (Novapak, 4µm, 
I50x3.9mm) using MeCN-H20 gradient (40:60 to 60:40) in 20 min (lml/min). 
The LC-MS analysis was carried out with a thermospray (TSP) interface 
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mounted on a triple quadrupole MS instrument (Finnigan MAT). Optimisation 
of the TSP parameters was performed by loop injection of pure artemisinin. 
The TSP LC-MS analyses were carried out in the positive ion mode with post 
column addition of buffer (ammonium acetate 0.5M, 0.2ml/min). The best 
sensitivity was found for a source temperature of 280°C and the vaporizer at 
90°C. The TSP spectra were recorded from 150-500 µ every 2 seconds. 
To test the detection limit of the method, one of the extracts, the cold 
dichloromethane extract of A. afra leaves, was spiked with lµg of artemisinin 
before being injected onto the HPLC column. 
4.9. Cultivation of parasite cultures 
Seven strains of P. falciparum were cultured routinely. They were DlO, FAC8, 
W2mef and W2mefQ from Dr. Alan Cowman, Walter Eliza Hall Institute, 
Melbourne, Australia; and RSA3, RSAl 1 and RSA15 obtained from Dr. Janet 
Freese, Medical Research Council, National Malaria Programme, Durban, 
South Africa. 
DlO originated from FCQ-27 in Papua New Guinea (73). FAC8 was 
regenerated from the ItG2 Fb strain in Brazil (74). W2mef was from W2 which 
had been drug-pressurized with mefloquine. The W2 strain originated from the 
hybridization of Indochina and Sierra Leone strains (75). W2mefQ was drug 
pressurized with chloroquine (76). There were 3 South African strains: RSA3, 
originated from North East Transvaal; RSAl l and RSA15 originated from 
KwaZulu-Natal (16). 
Type o+ human erythrocytes (obtained from Western Province Blood 
Transfusion Services and Haematology Department, U.C.T./G.S.H.) with 
Plasmodiumfalciparum i.e. parasitized red blood cells (PRBC) were cultured in 
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HEPES (N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid) (6g/l) buffered 
RPMI 1640 (BioWhittaker) culture medium supplemented with glutamine 
(10.4g/l), glucose (4g/l), hypoxanthine (44mg/I), gentamycin (40mg/ml), 0.2 % 
NaHC03 and 10% human A+ serum (obtained from Western Province Blood 
Transfusion Services and Haematology Department, G.S.H.) in tissue culture 
flasks (Corning) and incubated at 38°C. 
4.9.1. Changing medium 
Medium was changed daily. Cells were suspended at 5% hematocrit and with 
parasitaemia usually not more than 5 % . PRBC were centrifuged at 600g for 5 
minutes. The supernatant was removed and 1-2µ1 of PRBC were aspirated to 
prepare a smear. Fresh medium was added to the cell pellet and gently swirled. 
Uninfected type O + RBC were added every 3-4 days, or when parasitemia was 
greater than 10 % . The cell suspension was transferred to a tissue culture flask 
and flushed with filtered gas containing 3 % 0 2, 4 % CO2 and 93 % N2 for 20 
seconds. The lid was tightened and the flask was returned to the incubator. 
4. 9.2. Identification of parasites - staining of slides 
The blood smear was fixed with methanol and then covered with Giemsa stain 
(1 part Giemsa to 10 parts phosphate buffered saline (PBS)) for 5 minutes. The 
microslide was gently rinsed with water and allowed to air dry, before viewing 
under the microscope. 
4.9.3. Cryostorage and thawing 
Glycerol (28 % ) was prepared in PBS and filter sterilized using a 0.22µm filter 
(Millipore Millex-GS filter unit). This solution was then mixed with PRBC 
containing more than 1 % rings in a ratio 1: 1 (v/v). The suspension mixture 
(1ml) was transferred into cryotubes and dropped into liquid nitrogen. 
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Frozen parasites were thawed quickly at 37°C and transferred to a 10ml tube. 
Filter sterilized 3.5% NaCl (1ml/0.5ml cells) was added to the cell suspension, 
mixed well and allowed to stand for 1 minute. The cell mixture was centrifuged 
at 600g for 2 minutes and the supernatant discarded. The cell mixture was 
washed twice more with NaCl, and each time centrifuged and the supernatant 
discarded. Uninfected RBC and medium were added to the cell pellet. The cells 
were flushed with gas and placed in the incubator. 
4.10. Antimalarial screening 
This rapid, semi-automated microdilution method measures the activity of 
potential antimalarial drugs against cultured intraerythrocytic asexual forms of 
P. falciparum (32). Microtitration plates allow for quantitative measurement of 
the antimalarial activity of a number of compounds simultaneously. The assay is 
based on the inhibition of uptake of a radiolabelled nucleic acid precursor, 
hypoxanthine, by parasites. To avoid competition between the radiolabelled 
hypoxanthine and unlabelled hypoxanthine in culture medium for uptake by the 
parasites, hypoxanthine was excluded from the culture medium. 
4.10.1. Preparation of drugs and plant extracts 
Chloroquine (CQ) obtained from Sigma (diphosphate salt), was soluble in 
culture medium. Stock solution, lmg/ml was prepared (filter sterilized) and 
diluted in culture medium to yield the following final drug concentrations: 400, 
200, 100, 50, 10, 1, 0.1 and O.Olng/ml. 
Artemisinin and mefloquine were each dissolved in MeCN (HPLC grade), 
lmg/ml. Of this stock solution 18µ1 was transferred to an Eppendorf vial with 
medium so that the total volume was 1ml. From this sample further dilutions 
were prepared with the following final drug concentrations 100, 50, 10, 1, 0.1 
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and O.Olng/ml. The highest final concentration of MeCN that was used was 
0.002 % in the parasite culture. 
Stock solutions of 2mg/ml were prepared for the crude extracts, initially 
dissolved in MeCN and then diluted in culture medium to yield the following 
final concentrations: 100, 10, 1, and O. lµg/ml. The highest final concentration 
of MeCN was 0.56%. 
For all the fractions, stock solutions of lmg/ml in MeCN were diluted in culture 
medium to achieve final concentrations of 30, 10, 1, 0.5, 0.1, 0.01, 0.001 and 
0.0001 µg/ml with the highest final concentration of MeCN of 3% which had 
no adverse effect against DlO and FAC8. 
P6.2B (2mg/ml stock) also dissolved in MeCN was diluted in culture medium to 
yield final concentrations of 100, 10, 1, O. lµg/ml, with the highest MeCN 
concentration of 0.56%. 
For all the crude H20 extracts, lOOmg/ml stock solutions in culture medium 
were prepared and diluted so that final concentrations of 10 000, 1 000, 500, 
200, 100, 10, 1 and O. lµg/ml were achieved. 
4.10.2. Preparation of microtitration plates 
The microtitration plates used were 96 well flat-bottomed tissue culture plates 
(Bibby, Sterilin). First, 200µ1 of the parasite culture (haematocrit 1.5%, 
parasitemia 1 % ) was dispensed into each of the test wells using an Eppendorf 
dispenser and 200µ1 of 1.5 % of uninfected RBC, suspended in culture medium, 
was aliquotted to the control wells. Each drug concentration (25µ1) was then 
added to each of the test wells in triplicate by an Eppendorf dispenser. Culture 
medium (25µ1) was added to the control wells. All tests were conducted in 
triplicate. 
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A control experiment was set up to investigate the effects of MeCN against the 
P. falciparum strains. MeCN (25µ1) was added to wells containing 200µ1 
uninfected RBC (haematocrit 1.5 % ) and to wells containing PRBC (parasitemia 
0.5%, haematocrit 1.5%) so that the final MeCN concentrations were: 3.0, 
1.11, 0.56, 0.28, and 0.06 % . 
The plates were then placed in a desiccator and flushed with the gas mixture 
( described in section 4. 8.1.) for 2 minutes. The desiccator was sealed tightly 
and incubated for 24 hours at 38°C. After the 24 hour incubation period, the 
plates were removed from the desiccator and 25µ1 of the labelled hypoxanthine 
in culture medium, prepared as described below, was added to each well. The 
plates were then returned to the desiccator, flushed with the gas mixture for 2 
minutes, sealed and incubated (38°C) for a further 21 hours. 
4.10.3. Preparation of isotope 
[G-3H]-Hypoxanthine (Amersham) was used as an indicator of parasite growth. 
The isotope, supplied as a lyophylate (1 000 mCi/mmol) in ampoules containing 
1.0mCi, was dissolved in 2.0ml of 50% ethanol (filter sterilized) to provide a 
stock solution which was stored at 4°C. 
The ethanol of 0.1ml stock solution was evaporated using N2 gas. To the 
remaining 0.05ml of the isotope in water, 2.45ml of culture medium was added. 
Thus, the final isotope solution consisted of 20µCi of [G-3H]-hypoxanthine per 
ml culture medium. 
4.10.4. Harvesting of parasites 
At the end of the 21 hour incubation period, the plates were harvested using a 
PHD cell harvester (Cambridge Technology, Inc.). This instrument aspirated 
and deposited the particulate contents of each of the wells onto small discs of 
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glass fiber filter strips (Macherey-Nagel: retention 0.5µm, 0.4mm thickness) 
which were then washed 5 times with distilled water. Each disc was dried and 
placed in a plastic scintillation vial containing 4ml of scintillation cocktail 
(Packard Emulsifier Scintillator 299 for aqueous and non aqueous samples) and 
left on a shaker overnight. The vials were then counted (DPM) in a Packard Tri-
Carb 1900 CA liquid scintillation analyzer for 1 minute each. 
4.10.5. Analysis of data 
The mean DPM (disintegrations per minute) values for each drug or extract 
concentration and control wells were calculated. The mean DPM was then 
converted to a percentage of total [G-3H] hypoxanthine as follows: 
DPM of drug or extract ± SD - DPM of RBC control ± SD 
DPM of PRBC control ± SD - DPM of RBC control ± SD 
The percentage of [G-3H]-hypoxanthine incorporated (expressed as a percentage 
of the control) was then plotted against the logarithmic values of the 
corresponding drug concentrations (77). The inhibitory concentration of the 
drug or extract which results in 50% [G-3H]-hypoxanthine incorporation into the 
parasites is known as the IC50 value. IC50 values were calculated as follows: 
log (IC50) = log (x1) + ---
where two concentrations, x1 and x2 are such that the percentage [G-
3H]-
hypoxanthine incorporation, y1, at concentration x1 (and lower concentrations) is 
more than half of the percentage in the control, y0 , and the percentage [G-
3H]-
hypoxanthine incorporation found at x2 (and all higher concentrations) is less 
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than half of y0• The IC50 is then found by linear interpolation between x1 and x2 














Fig. 4: Schematic diagram demonstrating the interpolation method for 
calculating IC50 values. 
4.11. Cytotoxicity screening 
There was a need to distinguish a general cytotoxic effect from an antimalarial 
effect of the crude plant extract and its isolated pure compound. Hence the 3-
(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was 
set up (78). Viable cells are able to reduce the water-soluble yellow coloured 
MTT to a water-insoluble purple coloured formazan product. The amount of 
coloured formazan product formed, determined spectroscopically after 
dissolving the formazan crystals in DMSO, is proportional to the metabolic 
activity and the number of cells in the test sample. 
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4.11.1. Preparation of cell cultures 
A mammalian cell line, normal rat fibroblast cells, RA T-1, maintained in the 
Department of Medical Biochemistry, U. C. T., was used to screen for general 
cytotoxicity. The stock cultures, cultivated in sterile 75cm3 tissue culture flasks 
(NUNC) were sub-cultured every 5-7 days and kept at 37°C in an incubator that 
was continually flushed with 5 % CO2• Rat-1 cells were cultured in Dulbecco's 
Modified Earle's Medium (DMEM) containing 1 % of a mixture of penicillin 
(100 units/ml) and streptomycin (lOOµg/ml) and supplemented with 10% heat 
inactivated (55°C for 30 minutes) fetal calf serum (Highveld Biological). 
When cells were 90% confluent, a trypsin solution consisting of 0.25 % trypsin 
and 0.1 % EDTA in PBS, 5ml (BioWhittaker) was added and incubated for 5-10 
minutes at 37°C. An equal volume of culture medium was then added. Fetal calf 
serum, present in the medium inhibits further tryptic activity which could cause 
cell damage. 
To determine the cell density of the stock culture a Nebauer haemocytometer 
was used. Cells were also stained with trypan blue (Merck) which distinguished 
viable cells (which actively exclude trypan blue) from non-viable cells. From 
the stock culture a cell density of 10 000 cells/ml was prepared for addition to 
96-well microtitration plates. 
4.11.2. Preparation of drugs and plant extracts 
Colchicine was used as a standard. The antimalarial drugs, chloroquine, 
artemisinin and mefloquine were also tested so as to compare their toxicities 
with that of the crude plant extract and the isolated pure compound. Colchicine 
and chloroquine were dissolved in culture medium while the other samples to be 
tested were dissolved in HPLC grade MeCN and then serially diluted in culture 
medium. 
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For colchicine and chloroquine lmg/ml stock solutions were prepared and 
diluted to achieve the following concentrations: 1000, 500, 100, 10, 1, 0.1 
µg/ml. Stock solutions of lmg/ml in MeCN for artemisinin and mefloquine 
were also prepared and the following concentrations prepared: 100, 10, 1, 0.1 
µg/ml. The same concentrations: 100, 10, 1, 0.1 µg/ml were also prepared for 
the crude extract and P6.2B (stock solutions were however, lOmg/ml as 
opposed to lmg/ml). 
A control experiment was set up to investigate the effect of MeCN against the 
Rat-1 cell-line. A 10% stock solution was prepared and diluted 2-fold to yield 
the following concentrations: 10, 5, 2.5, 1.25, 0.625, and 0.3125 %. 
Each of the stock samples prepared above, were filter sterilized using a 0.22µm 
filter (Millipore Millex-GS filter unit) before being diluted. 
4.11.3. Preparation of microtitration plates 
To each well of a 96-well flat-bottom microtitration plate, with the exception of 
the wells in row 1, 200µ1 of the cell suspension (10 000 cells/ml) was added so 
that each well contained 2 000 cells. The 8 wells of row 1, contained 200µ1 of 
culture medium which served as a blank. The plates were then placed overnight 
in the incubator flushed with 5 % CO2 at 37°C to allow for cell adherance to the 
surface of each well in the plate. 
Following the overnight incubation period, medium was aspirated from each 
well and replaced with 200µ1 of the prepared drug or plant extract samples, with 
the exception of wells in rows 1 and 2. Medium only (200µ1) was added to the 
wells in rows 1 and 2. Since the wells of row 2 contained cells too, these wells 
served as the positive cell control while the wells of row 1 served as a blank. 
The plates were then incubated at 37°C for 68 hours. 
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4.11.4. Addition of MTT 
After the 68 hour incubation period, 50µ1 of MTI in PBS (lmg/ml) was added 
to each well. The plates were returned to the incubator for an additional 4 hours 
so that the total incubation time was 72 hours. The plates were then centrifuged 
at 600g for 10 minutes. Medium was carefully aspirated from each well without 
disturbing the formazan crystals. DMSO (100µ1) was then added to each well 
and gently shaken for 10 minutes to dissolve the crystals completely before 
being read at 540nm on a 7520 microplate reader (Cambridge Technology, 
Inc.). 
4.11.5. Analysis of data 
Cell viability at each concentration was determined. The mean absorbance and 
corresponding standard deviation for each concentration and positive cell 
controls were calculated. To determine the percentage cell viability for each 
concentration the following equation was used: 
average absorbance at a particular cone. ± SD 
% cell viability = 
average absorbance of the cell control ± SD 
Percentage cell viability was plotted against log concentration and IC5c values 
were calculated using the linear interpolation method (Fig. 4). 
4.12. Statistical analysis 
Statistical differences (p values) between IC50 values were obtained using the 
non-parametric two-tailed t-test for two independent means. The software 
package, Instat, was used. 
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5. Results 
5.1. Fractionation and purification of crude extract 
The number and mass of all the fractions produced from the fractionation 
process of the crude petroleum ether soxhlet extract of leaves and flowers from 
A. afra are recorded in Tables 1-3 below. 
Table 1: Yield of fractions obtained from 4.6g of crude A. afra as a result of 
column chromatography. 
Fraction Yield (mass in mg) % Yield 
Pl 219.2 4.77 
P2 171.2 3.72 
P3 308.0 6.70 
P4 312.2 6.79 
PS 171.5 3.73 
P6 400.2 8.70 
P7 290.0 6.30 
P8 1 020 22.17 
P9 1100 23.91 
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Table 2: Yield of fractions obtained from the most active antimalarial, fraction 
P6, 372mg, as a result of flash chromatography. 
Fraction Yield (mass in mg) % Yield 
P6.1 40 10.75 
P6.2 199 53.49 
P6.3 71 19.09 
P6.4 < 15 <4.03 
P6.5 15 4.03 
Table 3: Yield of fractions obtained as a result of further fractionation of 199mg 
of P6.2, the most abundant sub-fraction. 
Fraction Yield (mass in mg) % Yield 
P6.2A 16 8.04 
P6.2B 113.5 57.04 
P6.2C 31 15.58 
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5.2. Thin layer chromatography 
No artemisinin could be detected in any of the fractions obtained, in particular 
the most active fraction, P6. Fig. 5 shows the thin layer chromatographic profile 
of pure artemisinin used as a standard, and of A. afra. 
1 4-
Fig. 5: Thin layer chromatogram of artemisinin (lane l); crude extract of A. 
afra (lane 2); Fraction P6 (lane 3); and Fraction P6.2B (lane 4). The plate was 
developed twice in petroleum ether/ethyl acetate [3: l] and stained with 
anisaldeh yde. 
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5.3. HPLC analysis 
The HPLC chromatograms of artemisinin, P6.2B and the crude petroleum ether 
soxhlet extract of leaves and flowers are shown in Fig. 6-8. The retention times 
of artemisinin and P6.2B are 3.95 and 21.11 minutes respectively. Their UV 
spectra are also different, see Fig. 9. 
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Fig. 9: UV Spectra of artemisinin (black) and P6.2B (red). 
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In the chromatogram of the crude extract (Fig. 8) there are no peaks between 
2.5 and 11.5 minutes where artemisinin is likely to elute if present in the 
extract. The peak at 20.88 min is P6.2B. Its UV spectrum is similar to that of 
pure P6.2B. Their retention times are also similar. 
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HPLC chromatograms of all the crude extracts from A. afra in 1996 were also 
obtained. Their chromatographic profiles were compared to investigate 
differences, if any, between the two extraction techniques (i.e. cold extraction 
versus extraction in a Soxhlet apparatus), and between the different solvents 
used. Significantly, no artemisinin or P6.2B could be detected in any of the 
crude A. afra extracts of leaves or flowers, whereas P6.2B was isolated from the 
very first extract, which had been obtained from leaves and flowers. The 
absence of P6.2B in the more recent extracts, suggested that the compound 
could have been an artefact which had arisen from the extraction and/or 
fractionation of the crude extract. Alternatively, occurrence of P6.2B could be 
dependent on seasonal factors or developmental stages of the plant. 
Comparing the petroleum ether soxhlet extract of leaves to the cold 
dichloromethane extract of leaves (Fig. 10) it can be seen that the two solvents 
extracted the same compounds but in different amounts (peak heights were 
different between the two extracts). There were also a few additional peaks 
present only in the dichloromethane extract (± 20 min and 22 min). The cold 
water extract of leaves contained only a few minor compounds (Fig. 10) 
compared to the organic extracts. 
HPLC chromatograms of the petroleum ether soxhlet extract and the cold 
dichloromethane extract of flowers are shown in Fig. 11. The two solvents 
appear to have extracted the same number and quantity of compounds from A. 
afra. The chromatograms are not very different except at about 10 min where a 
few major peaks appear in the petroleum ether soxhlet extract only. The cold A. 
afra water extract of flowers also did not contain any major peaks (Fig. 11). 
The cold dichloromethane extracts between the leaves (Fig. 10) and flowers 
(Fig. 11) of A. afra were also compared. In the extract from leaves, compounds 
that elute between 18 and 30 min appear to be in larger amounts than in the 
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extract from flowers. However, between 8 and 9 min there are 2 peaks present 
in the extract from flowers that appear to be in larger quantities. 
The HPLC chromatograms of the petroleum ether soxhlet extracts of A. afra 
leaves (Fig. 10) and flowers (Fig. 11) were similar, except between 8.5 and 
about 10 min where there were a few major peaks present in the flowers extract, 
but not in the extract from leaves. 
The soxhlet water and cold water extracts from flowers of A. afra were 
compared (Fig. 12). There were a few peaks present in the cold extract only at 
2-10 min and at± 38 min. The peak at about 13 min occurs as a minor peak in 
the cold extract but as a major peak in the soxhlet water extract. The 
chromatogram of the cold petroleum ether extract of A. afra flowers is similar 
to the cold water extract of flowers (Fig. 12) than to the petroleum ether soxhlet 


























































































































































































































































































































































































































































































































































































































































































































































































5.4. Thermospray LC-MS analysis 
Under the given conditions for the TSP LC-MS analyses, artemisinin (0 .5µg) 
eluted at 10 min (Fig. 13). The TSP LC-MS spectrum of this compound showed 
intense peaks at m/z 283 and m/z 300 corresponding respectively to the 
[M + H]+ and [M + NH4t pseudomolecular ions of artemisinin (MW 282) in the 
different samples, thus allowing for very sensitive detection. 
In all three extracts, no artemisinin could be detected, i.e. no presence of the 
three ions m/z 237, 283 and 300 at 10 min or 290 scans (Fig. 14-16). 
The detection limit of the method showed that much less than lµg of artemisinin 
could easily be detected in the extract as there was an intense response for this 
compound in the TSP LC-MS trace (Fig. 17). This means that considerably less 
than 0.1 % of artemisinin could easily be detected in an extract. 
In each of the TSP LC-MS traces (Fig. 13-17) the reconstructed ion trace 
(RIC), the UV trace at 210nm (USER) and the m/z 237, 283 and 300 ion traces 
are displayed. TSP LC-MS spectrum of pure artemisinin standard is provided 
(Fig. 13). 
For each analysis 0-600 scans (i.e. 20 min) a full chromatogram is given 
together with an extension where artemisinin is to be detected at 250-350 scans. 
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Fig. 13: TSP LC-MS spectrum of artemisinin. Top to bottom: m/z 237, 283 and 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.5. Chemical identification of isolated compound 
Characterization (MS and NMR analyses) of the isolated pure compound, P6.2B 
was performed by Drs. B.M. Sehlapelo, D.W. Gammon and W.E. Campbell 
(Chemistry Department, U.C.T.). The compound was identified as 
hydroxydavanone (2,6, 10-trimethyl-7, 10-oxido-dodeca-3, 1 lE-dien-2-ol-5-one) 
which had been isolated previously from A. maritima L. spp. maritima (79), 
and A. herba alba Asso. from Morocco and Tunisia (80). In A. inculta Del. 
from Saudi Arabia (81) a highly oxygenated sesquiterpene, the hydroperoxide 
was isolated and could be transformed to the corresponding alcohol, 
hydroxydavanone. However, none of these compounds isolated had been tested 
for antimalarial activity. The molecular formula of hydroxydavanone is 
C1sH240 3 with MW 252.1860. 
Fig. 18: Chemical structure of hydroxydavanone. 
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5.6. Antimalarial activity 
All of the fractions were screened for in vitro antimalarial activity against 
Plasmodium falciparum using tritiated hypoxanthine. IC50 values of one 
experiment are reported in Tables 4 and 5 below. 
Table 4: Calculated IC50 values (µg/ml) of A. afra against P. falciparum in 
vitro. 
Sample DlO FAC8 
Crude 1.03 1.50 
Pl 5.4 >100 
P2 1.3 3.7 
P3 3.1 6.4 
P4 1.7 2.9 
P5 3.2 3.1 
P6 0.5 0.5 
P7 1.3 1.9 
P8 7.1 4.8 
P9 4.2 23.7 
CQ 0.023 0.142 
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P6.2D*: isolated pure compound 
FAC8 unfortunately was not available for screening at this time. Although the 
assay against FAC8 was performed at a later date, the results were negative, 
probably due to deterioration of the samples which had been stored in 
acetonitrile at -18°C. 
The two P. falciparum strains used thus far , D10 and FAC8, were characterized 
with respect to chloroquine, artemisinin and mefloquine. An additional 5 
strains, of which 3 were South African, were also included in this investigation. 
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Table 6: Mean IC50 values (ng/ml) of chloroquine against P. falciparum in 
vitro, where n is the no. of experiments performed. 
Strain Chloroquine n sensitive or resistant 
D10 23.23 ± 1.72 3 sensitive 
RSA3 21.03 ± 1.93 3 sensitive 
FAC8 142.4 ± 34.69 3 resistant 
W2mef 215.50 ± 50.16 3 resistant 
W2mefQ 252.40 ± 8.91 2 resistant 
RSAll 212.23 ± 47.68 3 resistant 
RSA15 265.50 ± 104.38 3 resistant 
D10 and RSA3 was not significantly different (p=0.2145). They were classified 
as chloroquine-sensitive. D10 and FAC8 were significantly different 
(p=0.0040). FAC8 was not significantly different to W2mef, p=0.1065 and 
W2me~Q' RSAll and RSA15 (p>0.1065). W2mef was not significantly 
different to W2mefQ (p=0.3997); the same applied to RSAll and RSA15 
(p=0.4664). These strains were classified as chloroquine-resistant. 
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Table 7: Mean IC50 values (ng/ml) of artemisinin against P. falciparum in vitro, 
where n is the no. of experiments performed. 
Strain Artemisinin n sensitive or resistant 
D10 11.30 ± 6.59 3 resistant 
RSA3 13.67 ± 7.96 3 resistant 
FAC8 2.67 ± 0.50 3 sensitive 
W2mef 3.13±0.15 3 sensitive 
W2mefQ 3.50 ± 0.96 3 sensitive 
RSAll 3.80 ± 0.80 3 sensitive 
RSA15 2.33 ± 1.00 3 sensitive 
-
With respect to artemisinin, D10 and RSA3 could be classified as artemisinin-
resistant. No significant difference was found between these two strains 
(p=0.7115). DlO was not significantly different to FAC8 (p=0.0865). Again, 
FAC8 was not significantly different to W2mef (p=0.2016); W2mef was not 
significantly different to W2mefQ (p=0.5456); and RSAl 1 was not 
significantly different to RSA15 (p=0.1177). These strains could be classified 
as artemisinin-sensitive. 
This trend of resistance was similar for mefloquine (Table 8) where D10 and 
RSA3 were not significantly different, p=0.0962. DlO and FAC8 were 
however, significantly different with p=0.0435. No significant difference was 
found for W2mef and RSAll (p=0.3695). DlO and RSA3 could be classified as 
67 
resistant although D10 confers greater sensitivity. FAC8, W2mef, W2mef
0 , 
RSAl 1 and RSA15 were classified as mefloquine-sensitive. 
Table 8: Mean IC50 values (ng/ml) of mefloquine against P. falciparum in vitro, 
where n is the no. of experiments performed. 
Strain Mefloquine n sensitive or resistant 
D10 24.30 ± 0.42 2 resistant 
RSA3 32.23 ± 4.43 3 resistant 
FAC8 10.77 ± 5.38 3 sensitive 
W2mef 14.90 ± 6.34 3 sensitive 
W2mef
0 14.90 ± 8.92 3 sensitive 
RSAll 10.30 ± 4.69 3 sensitive 
RSA15 10.77 ± 5.34 3 sensitive 
With respect to the isolated pure compound from A. afra, P6.2B (Table 9), D10 
and RSA3 was found to be significantly different with p=0.0375, while D10 
and FAC8 were not significantly different (p=0.9801). The highest activity was 
recorded against D10 and FAC8 with IC50 of 0.87 ± 0.04 and 0.88 ± 0.20 
µg/ml respectively. P6.2B had the lowest activity against RSA3; IC50 : 2.65 ± 
0.50 µg/ml. 
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Table 9: Mean IC50 values (µg/ml) of P6.2B against P. falciparum in vitro, 
where n is the no. of experiments performed. 
Strain P6.2B n 
DlO 0.87 ± 0.04 2 
RSA3 2.65 ± 0.50 2 
FAC8 0.88 ± 0.20 2 
W2mef 2.00 1 
W2mefQ 1.90 1 
RSAll 2.54 1 
RSA15 1.60 1 
Fig. 19 is a photograph of the various erythrocytic stages of the life cycle of P. 
falciparum cultured in vitro as observed under the microscope with 
magnification x 1600. 
Fig. 20-24 show the dose response curves of the crude petroleum ether soxhlet 
extract of A. afra, chloroquine, artemisinin, mefloquine and P6.2B against P. 
falciparum. 
Appendix C shows the dose response curves for the concentrations of MeCN 
used for the in vitro experiments against P. falciparum strains. Clearly, the 
concentrations used to dissolve artemisinin, mefloquine, P6.2B and crude 





Fig. 19: Erythrocytic stages of the life cycle of Plasmodium falciparum, 
cultured in vitro. Magnification x1600. 
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Fig. 20: The effect of the crude petroleum ether soxhlet extract of A. afra leaves 
and flowers on the incorporation of hypoxanthine into P. falciparum. Data 
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Fig. 21: The effect of chloroquine on the incorporation of hypoxanthine into P. 
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Fig. 22: The effect of artemisinin on the incorporation of hypoxanthine into P. 
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Fig. 23: The effect of mefloquine on the incorporation of hypoxanthine into P. 
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Fig. 24: The effect of P6.2B on the incorporation of hypoxanthine into P. 
falciparum. Data indicate means ± SD (n=2). 
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Table 10: Mean IC50 values (µg/ml) of 2 experiments of crude A. afra extracts 
against P. falciparum in vitro. 
Part of plant used Extract DlO FAC8 
Leaves DCM cold 4.31 ±0.45 2.91 ± 0.37 
P. E. soxhlet 6.26 ± 0.37 6.22 ± i.12 
H20 cold 645.02 ± 18.65 420.24 ± 14.28 
Flowers and Seedlings DCM cold 9. 79 ± 1.00 6.63 ± 0.81 
P.E. cold 29.25 ± 0.04 31.65 ± 0.35 
P.E. soxhlet 15.78 ± 2.09 17.99 ± 0.63 
H20 cold 1 400· 1 740* 
DCM: dichloromethane; P.E. petroleum ether; H20: water; ·: one experiment only. 
The antimalarial activities of the various crude extracts generated from A. afra 
are reported in Table 10. Statistical differences were determined. There was a 
significant difference between the cold dichloromethane and petroleum ether 
soxhlet extracts of leaves and flowers. When the cold dichloromethane and 
petroleum ether soxhlet extracts from leaves were tested against D 10 a p value 
of 0.0419 was obtained (therefore significantly different) and when tested 
against FAC8, a p value of 0.0580 was obtained (not significantly different). 
The cold dichloromethane and cold petroleum ether extracts of flowers were 
compared and were found to be very significantly different with p values of 
0.0013 against DlO and 0.0006 against FAC8. Dichloromethane, therefore 
extracted compound(s) with greater antimalarial activity. 
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When the cold petroleum ether extract and the petroleum ether soxhlet extract 
were compared for statistical difference, p values of 0.0118 and 0.0014 were 
obtained for D10 and FAC8 respectively. The difference was very significant 
with the extract obtained from the Soxhlet exhibiting a greater antimalarial 
effect. 
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5. 7. Cytotoxicity 
Colchicine was used as a standard (Fig. 25). Excluding colchicine, mefloquine 
was the most toxic against RAT-1 cells, followed by P6.2B, the crude A. afra 
extract, artemisinin and chloroquine. Statistical differences were also 
determined. There was no statistical difference between chloroquine and 
artemisinin (p=O. 7547). The statistical difference for mefloquine and 
artemisinin was extremely high with p=0.0004. There was a significant 
difference between mefloquine and the crude A. afra extract (p=0.0012) and 
with the crude A. afra extract and artemisinin (p=0.0489). The statistical 
difference between the crude extract and P6.2B was extremely significant with a 
p value of 0.0005. Throughout these experiments the highest percentage of 
MeCN used did not exceed 1 % which had no adverse effect against the RA T-1 
cell-line (Appendix D). 
Table 11: Mean IC50 values (µg/ml) of P6.2B against RAT-1 cells, in vitro, 
where n is the no. of experiments performed. 
Sample Mean IC50 ± SD (µg/ml) n 
Chloroquine 53.58 ± 13.33 3 
Artemisinin 50.61 ± 7.65 3 
Crude extract of A. afra 34.78 ± 8.23 4 
P6.2B 6.29 ± 0.95 4 
Mefloquine 2.55 ± 0.12 3 
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Fig. 25: Cytotoxic effects of P6.2B against RAT-1 fibroblast cells. Data 
indicate means± SD (n=4) . The y-axis represents cell viability as a percentage 
of the control. 
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5.8. Selectivity Index 
The selectivity index (i.e. ratio of cytotoxicity to antimalarial activity) was 
calculated for P6.2B, the crude A. afra extract, chloroquine, artemisinin and 
mefloquine. Ratios < 1 indicate higher cytotoxicity than antimalarial activity 
(82). 
Table 12: Selectivity indices i.e. mean IC50 for cytotoxicity/mean IC50 for 
antimalarial activity. 
Strain CQ QHS MEF P6.2B Crude 
D10 2 307 4 479 105 7.2 33.8 
RSA3 2 548 3 702 79 2.4 23.2 
FAC8 376 18 955 237 7.1 nd 
W2mef 249 16 169 171 3.1 nd 
W2mefQ 212 14 460 171 3.3 nd 
RSAll 253 13 318 248 2.5 nd 
RSA15 202 21 721 237 3.9 nd 
CQ: chloroquine; QHS: artemisinin; MEF: mefloquine; Crude: A. afra extract; nd: not d~termined. 
The highest selectivity indices were recorded for artemisinin, which ranged 
from 3 702 to 18 955. The selectivity index for chloroquine, was higher for the 
chloroquine-sensitive strains, D10 and RSA3 (2 307 and 2 548 respectively), 
than for the chloroquine-resistant strains, which ranged from 202 to 376. The 
selectivity index for mefloquine ranged from 79 to 248 for the P. falciparum 
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strains tested. The crude extract from A. afra, from which P6.2B was isolated, 
had ratios of 33.8 and 23.2 against DlO and FAC8 respectively. P6.2B had the 
lowest selectivity indices recorded; range: 2.4 - 7.2. 
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6. Discussion 
A crude petroleum ether soxhlet extract of leaves and flowers from A. afra had 
previously been shown to exhibit antimalarial activity against P. falciparum in 
vitro (6). The main objective of this project was to undertake a bioassay-guided 
fractionation process of this crude extract in order to identify the active principle 
and to determine whether artemisinin could be responsible for the antimalarial 
effect. 
The crude extract (4.6g) was chromatographed on a silica gel column to yield 
120 fractions. The column was initially washed with petroleum ether, which 
eluted most of the plant waxes. The petroleum ether fractions solidified at room 
temperature and were insoluble in a number of organic solvents, including 
acetonitrile. Consequently, they were excluded from the antimalarial screening. 
After petroleum ether was used, a small percentage of ethyl acetate was 
introduced into the eluant mixture and gradually increased until the eluant 
mixture was 100% ethyl acetate. The column was finally washed with 100% 
methanol. The early fractions collected would have contained most of the non-
polar compounds and the later fractions would contain the more polar 
compounds. These fractions were pooled on the basis of their TLC profiles 
which resulted in a total of 9 fractions, labelled Pl to P9. Fractions PS and P9 
were the methanol fractions. The percentage yields of fractions Pl-P9 are 
summarized in Table 1. 
Each fraction was then screened for in vitro antimalarial activity against 
chloroquine-sensitive (D 10) and chloroquine-resistant (F ACS) strains of P. 
falciparum. Their IC50 values are reported in Table 4. Fraction P6 had the 
highest antimalarial activity i.e. lowest IC50 value of O.Sµg/ml against both 
strains. Its activity had also increased from that of the crude extract which was 
1.03 and 1.50 against D10 and FAC8 respectively, whereas the other IC50 
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values obtained which ranged from 1.3 to 23.7µg/ml had increased from that of 
the crude extract. Interestingly, fraction Pl had an IC50 value of 5.4µg/ml 
against Dl0 but an IC50 value greater than lOOµg/ml against FAC8. It is 
possible that there is a compound(s) present in this fraction that could be 
transported into the parasite in a similar way as for chloroquine, such that there 
is less accumulation in the chloroquine-resistant strain, FAC8. This fraction 
warrants further investigation. 
Following a bioassay-guided fractionation approach, the most active fraction, 
fraction P6 was to be further fractionated. It was therefore subjected to flash 
chromatography and another 5 fractions were produced, denoted P6. l to P6.5. 
Their masses and percentage yields are recorded in Table 2. The largest of these 
fractions, P6.2 was subjected to further chromatography to yield 3 sub-fractions 
(Table 3) of which one, P6.2B, a clear colourless oil, appeared to be a single 
pure compound from TLC analysis. This compound was the major constituent 
of fraction P6.2. 
At this point all the sub-fractions were screened against Dl0 to investigate their 
antimalarial activity and to determine which sub-fraction contained the active 
principle (Table 5). All the sub-fractions were active against Dl0 with IC50 
values ranging from 0.95 to 21.0µg/ml. Fraction P6.2B had the highest 
antimalarial activity with an IC50 of 0.95µg/ml. Of the sub-fractions generated 
from fraction P6.2 it was clear that P6.2B was the most active. The decrease in 
antimalarial activity of fraction P6 from 0.5 µg/ml to 0.95µg/ml in fraction 
P6.2B suggests that components in the extract, including compound P6.2B, 
could be acting in synergy to be effective against P. falciparum. It would be of 
interest to reconstitute the fractions and then screen for antimalarial activity to 
see if the activity is the same as before. 
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When fraction P6.2B was run on HPLC-UV it became apparent that P6.2B was 
a single pure compound as it exhibited a single, sharp peak (Fig. 7). P6.2B also 
migrated as a single spot on TLC in different solvent mixtures of petroleum 
ether, dichloromethane, ethyl acetate and methanol (results not shown). High 
resolution mass spectrometry revealed a mass of 252.1860, consistent with a 
molecular formula of C15H240 3 • The compound was identified by MS and NMR 
analyses as hydroxydavanone (Fig. 18) in the Chemistry Department at U.C.T. 
Hydroxydavanone had been isolated previously from two other species of 
Anemisia. It was first identified in A.maritima L. spp. maritima (79) and then 
later isolated from A. herba alba (80). This compound had not been tested 
previously for antimalarial activity. In A. inculta and A. herba alba the 
hydroperoxide analoque of hydroxydavanone was found (80,81) as well as a 
number of davanone-like derivatives in A. herba-alba (80). 
The antimalarial activity of the most active fraction, P6, was not due to 
artemisinin since hydroxydavanone was identified as the antimalarial compound. 
This was confirmed by a TLC comparison of pure artemisinin, A. afra crude 
extract, fraction P6 and fraction P6.2B (Fig. 5) which showed the absence of 
artemisinin in fractions P6 and P6.2B. Different UV spectra were obtained for 
artemisinin and P6.2B by HPLC-UV analysis (Fig. 9). There was however, still 
the question of artemisinin occurring in crude extracts of A. afra. 
In the study thus far, neither TLC nor HPLC analyses had detected artemisinin 
in any of the crude A. afra extracts. To confirm this result, 3 samples of crude 
A. afra extracts (i.e. the crude petroleum ether soxhlet extract of leaves and 
flowers from which hydroxydavanone was isolated, crude petroleum ether 
soxhlet extract of leaves and the cold dichloromethane extract of leaves) were 
sent to Prof. K. Hostettmann at the University of Lausanne, Switzerland, for an 
accurate detection of artemisinin using thermospray LC-MS. The results showed 
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that no artemisinin could be detected in any of the three samples (Fig. 14-16). 
The detection limit showed that much less than lµg (i.e. less than 0.1 % ) of 
artemisinin could be detected easily in the extract (Fig. 17). Although it was 
deemed possible that there could be trace amounts of artemisinin in the extracts, 
this however, seemed unlike! y. 
It therefore appears that there is no artemisinin in A. afra, although two factors 
cannot be discounted as explanations for its absence from the crude extracts. 
Firstly, it had been reported that the highest amount of artemisinin in A. annua 
was isolated just before flowering of the plant (3,4). A. afra in these 
experiments had been harvested before the flowering stage or whilst in the 
flowering stage. Verification of these results would require a systematic study of 
extracts prepared from A. afra at various stages of growth. Secondly, it was 
thought that if artemisinin was indeed present in A. afra extracts, then the 
possibility exists that it could be decomposed or degraded as a result of the 
extraction process which involved heating of the solvent up to 80°C in the 
Soxhlet apparatus. This theory however, seemed unlikely as artemisinm was, 
and continues to be regularly isolated from A. annua using a Soxhlet apparatus 
and it is known to be stable in non-polar solvents (3,38,71). 
In an attempt to collect more plant material in order to isolate more of 
compound P6.2B, A. afra was collected in January 1996, which was before the 
flowering season. The material was dried and divided into 3 portions. These 
portions were extracted with hot petroleum ether (Soxhlet apparatus) and cold 
(room temperature) extractions with dichloromethane and water were 
performed. Surprisingly, hydroxydavanone could not be detected in any of the 3 
extracts. A further sample of A. afra was harvested from the same bush at 
Kirstenbosch in May 1996, at the end of the flowering season. The material 
collected had few flowers left and seeds were already developing. The material 
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was nevertheless dried and portions extracted with hot petroleum ether (Soxhlet) 
and cold petroleum ether, dichloromethane and water. Using HPLC-UV, no 
P6.2B could be detected in any of these extracts either. This leads to the 
conclusion that hydroxydavanone could be present only for a short while, at the 
beginning of the flowering of the plant. The possibility also exists that the 
compound could be an intermediate secondary metabolite such that it is present 
only for a short while, at a particular stage of plant development. Finally, there 
is the possibility of hydroxydavanone being an artefact of the original soxhlet 
extraction procedure. 
Samples of all the crude A. afra extracts generated in 1996 were injected 
(200µg) on a reverse phase C18 column. Their HPLC chromatograms are shown 
in Fig. 10-12. The chromatographic profiles were compared to determine any 
differences between the soxhlet and cold extraction techniques, and the different 
solvents used. In vitro antimalarial activities of these crude extracts were also 
determined against two strains of P. falciparum, namely, D10 and FAC8 (Table 
10). The organic solvents, excluding the cold extraction with petroleum ether, 
demonstrated greater efficiency in extracting the larger number and quantity of 
antimalarial compounds. None of the 3 extracts from leaves of A. afra were as 
active (IC50s ranged from 2.91 ± 0.37 to 645.02 ± 18.65 µg/ml against D10 and 
FAC8) (Table 10) as the first extract from leaves and flowers (IC50s of 1.03 and 
1.50 µg/ml against D10 and FAC8 respectively) (Table 4). The H20 extract of 
A. afra leaves had very low activity (IC50 of 645.02 ± 18.65 µg/ml against D10) 
compared to the organic extracts (IC50s of 4.31 ± 0.45 and 6.26 ± 0.37 µg/ml 
against D 10 for the cold dichloromethane and petroleum ether soxhlet extracts 
respectively) (Table 10). The cold dichloromethane extraction technique 
appeared to have the greater extraction efficiency as it extracted compounds in 
larger amounts than the petroleum ether soxhlet extract of leaves (Fig. 10). 
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Comparing the two extraction techniques with petroleum ether for flowers of A. 
afra (Fig. 11 and 12), it is clear that the soxhlet extraction technique proved to 
be more effective in extracting the antimalarial compound(s) as the petroleum 
ether soxhlet extract had greater antimalarial activity (IC50s of 15. 78 ± 2.09 and 
17.99 ± 0.63 µg/ml against DlO and FAC8 respectively) than the cold 
petroleum ether extract (IC50s of 29.25 ± 0.04 and 31.65 ± 0.35 µg/ml against 
DlO and FAC8 respectively). The cold dichloromethane extract of flowers also 
had greater antimalarial activity (IC50s of 9. 79 ± 1.00 and 6.63 ± 0.81 µg/ml 
against D 10 and F AC8 respectively) than the cold petroleum ether extract of 
flowers. This result was not surprising since the cold dichloromethane extract 
contained larger amounts of compounds compared to that of the cold petroleum 
ether extract of A. afra flowers (Fig. 12). 
The cold dichloromethane and water extracts of A. afra flowers had less activity 
against P. falciparum compared to the activities obtained for the extracts of 
leaves (Table 10). Antimalarial activity was therefore, found to vary according 
to the developmental stage of the plant. The leaves of A. afra give way to 
flowers as they are formed. The crude petroleum ether soxhlet extract of A. afra 
leaves and flowers, from which hydroxydavanone was isolated, had the highest 
antimalarial activity against DlO and FAC8 (IC50s were 1.03 and 1.50 µg/ml 
respectively). The plant material had been harvested at the start of the flowering 
season. Therefore, there may also be seasonal variations that could influence 
antimalarial activity of the plant. 
The antimalarial activity of hydroxydavanone or P6.2B was investigated against 
a variety of P. falciparum strains with varying degrees of sensitivity against 
chloroquine and mefloquine. These included 3 South African strains also with 
varying sensitivity against chloroquine. Artemisinin was also screened against 
these strains. The results are summarized in Tables 6-9 and figures 21-24. 
87 
The P. falciparum strains D 10 and RSA3 could be classified as chloroquine-
sensitive and FAC8, W2mef, W2mef
0 , RSAll and RSA15 could be classified 
as chloroquine-resistant. The IC50 values obtained were in good agreement with 
literature values (16,76,83). FAC8 had the mildest resistance against 
chloroquine with IC50 of 142.4 ± 34.69ng/ml as compared to RSA15, the most 
chloroquine-resistant strain: IC50 of 265.50 ± 104.38ng/ml. W2mef
0 was more 
resistant to chloroquine than W2mef. The chloroquine-sensitive strains, DlO and 
RSA3 had similar IC50 values of 23.23 ± 1.72 and 21.03 ± 1.93 ng/ml 
respectively. 
The trend of resistance of chloroquine was different for mefloquine. The 
chloroquine-sensitive strains, DlO and RSA3 were mefloquine resistant whereas 
the chloroquine-resistant strains, FAC8, W2mef, W2mefQ, RSAll, and RSA15 
were more sensitive to mefloquine. This is also in good agreement with 
literature values (1). DlO and RSA3 had IC50 values of 24.30 ± 0.42 and 32.23 
± 4.43 ng/ml respectively. The range of IC50 values for FAC8, W2mef, 
W2mefQ, RSAll and RSA15 ranged from 10.30 ± 4.69 to 14.90 ± 8.92 ng/ml. 
A similar trend as for mefloquine could be observed for artemisinin. However, 
all the strains were more sensitive to artemisinin than to mefloquine. D 10 and 
RSA3 had IC50s of 11.30 ± 6.59 and 13.67 ± 7.96 ng/ml respectively. The IC50 
values for FAC8, W2mef, W2mef0 , RSAll and RSA15 ranged from 2.67 ± 
0.50 to 3.80 ± 0.80 ng/ml. 
P6.2B was active against all 7 strains of P. falciparum but in the µg/ml 
concentration range. The highest activity was against D 10 and F AC8 with IC50s 
of 0.87 ± 0.04 and 0.88 ± 0.20 µg/ml respectively. Note that when previously 
tested against DlO, an IC50 value of 0.95µg/ml was obtained. Therefore, there 
is a good indication of the stability of the compound and reliability and 
reproducibility of the antimalarial assay. The IC50 obtained for RSA3 was 
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higher at 2.65 ± 0.50µg/ml. As for mefloquine, there was a statistical difference 
between D10 and RSA3. However, D10 and FAC8 were not significantly 
different. There was, however, a difference between the IC50 values of D10 and 
the remaining chloroquine-resistant P. falciparum strains which ranged from 
1.60 to 2.54 µg/ml. 
With the antimalarial activity of P6.2B confirmed, it was important to establish 
its cytotoxicity profile to investigate its potential for clinical use. To provide 
some perspective, the cytotoxic profiles of chloroquine, artemisinin and 
mefloquine in addition to colchicine which was used as a standard, were also 
investigated. The crude A. afra extract of leaves and flowers was also screened. 
The cytotoxic activities against RAT-1 cells are reported in Table 11 and 
illustrated in Fig. 25. Colchicine had the highest cytotoxicity with IC50 : 0.60 ± 
0.47 µg/ml. Mefloquine had the second highest activity followed by P6.2B, the 
crude A. afra extract, artemisinin and chloroquine. Throughout these 
experiments the highest percentage of acetonitrile that was used did not exceed 
1 % which had negligible effect against RAT-1 cells (Appendix D). From the 
above data, it is clear that both the crude A. afra extract and P6.2B have greater 
antimalarial activity (IC50 of ±lµg/ml for both the crude extract and P6.2B) than 
cytotoxic activity (34.78 ± 8.23 and 6.29 ± 0.95 µg/ml for the crude A. afra 
extract and P6.2B respectively). The cytotoxic activity for P6.2B is higher than 
the crude A. afra extract. This probably accounts for the higher antimalarial 
activity of P6.2B (IC50s of 0.87 and 0.88 µg/ml against D10 and FAC8 
respectively) over the crude extract of A. afra (IC50s of 1.03 and 1.50 µg/ml 
against D10 and FAC8 respectively). 
P6.2B had the lowest selectivity indices which ranged from 2.4 to 7.2 compared 
to the other antimalarials tested (Table 12). The selectivity indices for the crude 
A. afra extract was also low (33.8 and 23.2 against Dl0 and FAC8 
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respectively). It has been proposed that the ratio for a good therapeutic remedy 
be ~ 1 000, as for quinine (82). Artemisinin clearly satisfies this criterion with 
selectivity indices ranging from 3 702 to 18 955 for the parasite strains tested. 
The selectivity indices for chloroquine against the chloroquine-sensitive strains 
was considerably higher (~ 2 307) than for the chloroquine-resistant strains of 
P. falciparum which ranged from 202 to 376. Selectivity indices for 
mefloquine, a drug in clinical use, were much less than 1 000 although greater 
than 1. 
It is important to note that it is difficult to correlate results of this study directly 
with the effects of a traditional treatment, since there are a number of factors 
that need to be considered, for example, the methods of preparation, the effects 
of a combination of plant extracts, as well as storage conditions. These factors 
could also potentially affect reproducibility of the data. In this study, these 
factors have not been considered and may be significant. Although a soxhlet 
extraction with water of flowers from A. afra was prepared, there is doubt that 
its activity would have been as high as for the organic extractions based on the 
following observations. Early attempts to confirm antimalarial activity of a hot-
water (Soxhlet) extract of A. annua had been disappointing (3). Results were 
more encouraging with a low-temperature extraction of the plant with an organic 
solvent such as ethyl ether (3). 
In the laboratory it is also difficult to study the effects of a combination of 
extracts. Together with the age of the plant and seasonal variations, there are 
additional factors that could affect reproducibility of data, such as regional and 
even geographic variations. In fact, distinct chemical differences by both TLC 
and HPLC-UV analyses, was observed between crude petroleum ether soxhlet 
extracts of two A. afra bushes at Kirstenbosch which were less than 5 metres 
apart (results not shown). It is also possible that many traditional healers 
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prescribe plants for their antipyretic properties as opposed to direct antimalarial 
effects (65). It is recognized that no attempt was made in this study to 
investigate this type of activity in A. afra so that its possible antipyretic 
therapeutic value is not recognized. 
Since aerial parts of the plant are harvested as opposed to the roots, harvesting 
does not lead to plant death. Greater antimalarial activity has been reported for 
the aerial parts of the plant than roots (65). Thus, demonstration of activity in 
the aerial parts has implications for the sustainable agriculture and harvesting of 
plants. 
In spite of the selectivity indices for P6.2B being low, there is still potential for 
this compound to be used clinically. Animal studies e.g. mice infected with P. 
berghei are recommended to assess its clinical potential. Structure modifications 
of hydroxydavanone could result in new chemical structures with increased 
potency against strains of P. falciparum, both in vitro and in vivo. There is also 
scope for this compound to be studied in combination with other antimalarials. 
For example, hydroxydavanone could enhance the activity of chloroquine, 
especially against chloroquine-resistant strains of P. Jalciparum. Also, just as 
synergistic effects were observed between artemisinin and mefloquine, similar 
synergy could be observed between hydroxydavanone and artemisinin or 
mefloquine. On the other hand, it is possible that the effect(s) of a combination 
of antimalarials, together with hydroxydavanone could be additive. 
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7. Conclusion 
Crude extracts of A. afra exhibit in vitro antimalarial activity against 
chloroquine-sensitive (D 10) and chloroquine-resistant (F ACS) strains of P. 
falciparum. The crude petroleum ether soxhlet extract of leaves and flowers had 
been successfully fractionated, resulting in the isolation of a single pure 
compound which was active against a variety of P. falciparum strains, including 
all three South African strains tested. This compound, a clear colourless oil was 
identified as hydroxydavonone. Cytotoxic screening was performed against a 
RA T-1 fibroblast cell-line which revealed greater antimalarial activity than 
cytotoxic activity for both the crude extract and the pure compound. Although 
selectivity indices for the crude petroleum ether soxhlet extract of leaves and 
flowers from A. afra were higher than those of the isolated pure compound, 
there are implications for this compound to be used clinically as an antimalarial 
but further studies are required to assess its potential. This suggests a role for A. 
afra as a phytomedicine in malaria. Furthermore, the demonstration of activity 
in the aerial parts of the plant has implications for the sustainable agriculture 
and harvesting of plants. 
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Principle of the Soxhlet Extraction: The plant material is placed in A, the 
Soxhlet apparatus. The apparatus is then fitted onto flask C, which contains the 
solvent. The solvent is boiled gently. Vapour passes up through the tube E 
which is condensed by the condenser D. The condensed solvent falls into A and 
slowly fills the body of the Soxhlet. When the solvent reaches the top of tube F, 
it siphons over into flask C and thus removes that portion of the substance 
which it has extracted in A. This process is repeated automatically until the 
extraction is complete, usually over several hours. The extracted compound is 
then isolated from C by evaporating the solvent (84). 
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Appendix B 
N Collar endplate 
A Absorbent 
X Shaft collar 
FMotor / 
G Output tube 
Principle of the Chromatotron: Chromatography is performed in a thin layer 
of absorbent A on a rotor B. A motor F drives the rotor at a constant speed by a 
shaft passing through a hole in the centre of the main vessel D. Solutions of 
compounds to be separated are applied to the absorbent via the inlet I and wick 
J. Elution by solvent forms concentric bands of separated substances which 
leave the edge of the rotor together with solvent. A channel E collects the eluate 
and brings it to the output tube G. The Teflon lid C is transparent to UV light, 
allowing detection of UV absorbing bands. Eight retaining clips H hold the 
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The effect of acetonitrile on the incorporation of hypoxanthine into P. 
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The effect of acetonitrile against RA T-1 fibroblast cells. Data indicate means ± 
SD (n=2). IC50 value: 5.63 ± 0.15%. For all experiments conducted the 
amount of acetonitrile used did not exceed 1 % . 
